

Dave L. Dixon, Pharm.D., BCACP, CLS, FACC, FAHA, FCCP, FNLA

Updated: 7/31/26

Nancy and Ronald McFarlane Professor (*Tenured*) of Pharmacy
Chair, Department of Pharmacotherapy & Outcomes Science
Virginia Commonwealth University (VCU) School of Pharmacy
410 N. 12th St., Box 980533, Richmond, VA 23298-0533

Mobile: (804) 525-0685 | **Office:** (804) 628-3784 | **Email:** DLDixon@vcu.edu

EDUCATION & TRAINING

PGY-1 Primary Care Residency (ASHP-accredited) 2006-2007
Charles George VA Medical Center, Asheville, NC

Doctor of Pharmacy (Pharm.D.) 2002-2006
Campbell University College of Pharmacy & Health Sciences, Buies Creek, NC

Pre-Pharmacy Undergraduate Coursework 1999-2002
Campbell University, Buies Creek, NC

ACTIVE LICENSURES AND CERTIFICATIONS

Certified Lifestyle Coach, National Diabetes Prevention Program 2019-Present
Board Certified Ambulatory Care Pharmacist (BCACP) 2016-Present
Clinical Lipid Specialist (CLS) 2012-Present
Licensed Pharmacist, Virginia 2011-Present
Licensed Pharmacist, North Carolina 2006-Present

PROFESSIONAL DEVELOPMENT

Collaboration and Influence Executive Education [Online], UVA Darden School of Business 2023
VCU Department Chair Certification Program, Grace E. Harris Leadership Institute 2021
VCU Leadership Program, Grace E. Harris Leadership Institute 2015-2016

ACADEMIC APPOINTMENTS

Faculty Appointments (VCU School of Pharmacy)

Professor (*Tenured*), Nancy and Ronald McFarlane Professor of Pharmacy 2022-Present
Associate Professor (*Tenure-Eligible*) 2019-2022
Associate Professor (*Term*) 2016-2019
Assistant Professor (*Term*) 2012-2016

Administrative Appointments (VCU School of Pharmacy)

Chair, Department of Pharmacotherapy & Outcomes Science Nov 2021-Present
 • Interim Chair June 2021-Oct 2021
Director, Center for Pharmacy Practice Innovation May 2017-Dec 2021
 • Interim Director Aug 2016-Apr 2017
Vice-Chair of Clinical Services, Department of Pharmacotherapy & Outcomes Science Aug 2015-June 2021

Affiliate Faculty Appointments

Professor, Department of Kinesiology and Health Sciences, VCU College of Humanities & Sciences 2023-Present
Professor, Internal Medicine (Division of Cardiology), Pauley Heart Center, VCU School of Medicine 2022-Present
Professor, Gulf Medical University College of Pharmacy, United Arab Emirates 2021-Present
Core Faculty, VCU School of Pharmacy Center for Pharmacy Practice Innovation 2015-Present

CLINICAL APPOINTMENTS

Ambulatory Care Pharmacist, Cardiology

2012-Present

VCU Health, Cardio Pharmacotherapy Clinic, Richmond, VA

- Provided comprehensive cardiovascular risk management under a collaborative practice agreement within an academic cardiology clinic (currently 0.5 day/week), independently initiating, modifying, and discontinuing pharmacotherapy and ordering/interpreting laboratory tests for dyslipidemia, obesity, hypertension, and chronic heart failure.
- Co-created the Cardio Pharmacotherapy Clinic with Antonio Abbate, MD, PhD

Ambulatory Care Pharmacist, Primary Care

2012-2019

Center for Healthy Hearts, Richmond, VA

- Provided comprehensive cardiovascular risk management under a collaborative practice agreement within an inner-city free clinic, independently initiating, modifying, and discontinuing pharmacotherapy and ordering/interpreting laboratory tests for dyslipidemia, diabetes, hypertension, and chronic heart failure (including high-risk and treatment-resistant populations).

Ambulatory Care Pharmacist, Cardiology and Internal Medicine

2007-2011

Atrium Health Wake Forest Baptist, Winston-Salem, NC

- Provided comprehensive medication management as a Clinical Pharmacist Practitioner within an academic medical center clinic, independently initiating, modifying, and discontinuing pharmacotherapy and ordering/interpreting laboratory tests for dyslipidemia, diabetes, antiarrhythmic drug therapy monitoring, and chronic heart failure (including high-risk and treatment-resistant populations).
- Co-created the lipid clinic, antiarrhythmic drug therapy monitoring clinic, and employer-sponsored diabetes management program.

HONORS AND AWARDS

National and International

Faculty Inductee, Lambda Chapter, Rho Chi (Pharmacy Academic Honor Society)	2026
Recognized in Stanford Elsevier World's Top 2% Scientists	2024, 2025
Delta Theta Chapter, Alpha Alpha Alpha (National First-Generation College Student Honor Society)	2024
Achievement Award, ACCP Ambulatory Care Practice & Research Network	2023
Clinical Practice Award, ACCP Cardiology Practice & Research Network	2022
Outstanding Reviewer, <i>Journal of the American College of Clinical Pharmacy</i>	2020
Fellow, American Heart Association (FAHA)	2021
Outstanding Reviewer, <i>Pharmacotherapy</i>	2018
President's Service Award, Southeast Chapter, National Lipid Association	2018
Fellow, American College of Cardiology (FACC)	2017
Member Recognition Award, ACCP Ambulatory Care Practice & Research Network	2016
Fellow, American College of Clinical Pharmacy (FCCP)	2016
Outstanding Contribution in Reviewing, <i>Journal of Clinical Lipidology</i>	2015
Innovations in Teaching Award, American Association of Colleges of Pharmacy	2014
Fellow, National Lipid Association (FNLA)	2014
Interprofessional Education Collaborative Development Award, Association of American Medical Colleges	2013
Alpha Zeta Chapter, Phi Lambda Sigma (Pharmacy Leadership Society)	2003
Delta Lambda Chapter, Kappa Psi (Oldest and Largest Pharmaceutical Fraternity)	2002

Research and Scholarship

Best Paper Awards

- Literature Award in Pharmacy Practice Research, American Society of Health-System Pharmacy (for "Cost-Effectiveness of Pharmacist Prescribing for Managing Hypertension in the United States") 2024
- Outstanding Paper of the Year Award, ACCP Ambulatory Care Practice & Research Network (for "Cost-Effectiveness of Pharmacist Prescribing for Managing Hypertension in the United States") 2024
- Outstanding Paper of the Year Award, ACCP Cardiology Practice & Research Network (for "Cost-Effectiveness of Pharmacist Prescribing for Managing Hypertension in the United States") 2024

Most Cited / Top Downloaded / Viewed Papers

- Top 10% Most-Viewed Paper, *Pharmacotherapy* (for "Current and emerging PCSK9-directed therapies to reduce LDL-C and ASCVD risk: A state-of-the-art review") 2026
- Top 10% Most-Viewed Paper, *Diabetes/Metabolism Research and Reviews* (for "Chrono-Nutrition for Hypertension") 2026
- Highest Readership Award, *Journal of the American Geriatrics Society* (for "Managing Hypercholesterolemia in Adults Older Than 75 years Without a History of Atherosclerotic Cardiovascular Disease: An Expert Clinical Consensus from the National Lipid Association and the American Geriatrics Society") 2026
- Top Cited Article, *Pharmacotherapy* (for "Incretin Hormone Agonists: Current and Emerging Pharmacotherapy for Obesity Management") 2026
- Most Read Article, *Canadian Journal of Physiology and Pharmacology* (for "Repurposing incretin therapies: a narrative review of emerging indications across cardiometabolic, liver, kidney, neurological, psychiatric, and other systems") 2025
- Top 10% Most-Viewed Paper, *Pharmacotherapy* (for "Role of Lipoprotein(a) in Atherosclerotic Cardiovascular Disease: A Review of Current and Emerging Therapies") 2024
- Top 10% Most-Downloaded paper, *Journal of the American College of Clinical Pharmacy* (for "Overview of Clinical Practice Guideline Development, Application to Pharmacy Practice, and Roles for Pharmacists") 2023
- Top Cited Paper, *Pharmacotherapy* (for "Meta-analysis of clinical outcomes of PCSK9 modulators in patients with established ASCVD") 2022
- Top Cited Paper, *Pharmacotherapy* (for "Omega-3 fatty acids for the prevention of atherosclerotic cardiovascular disease") 2021
- Top 10% Most-Downloaded paper, *Journal of Internal Medicine* (for "Pharmacologic strategies to reduce cardiovascular disease in type 2 diabetes mellitus: focus on SGLT-2 inhibitors and GLP-1 receptor agonists") 2019
- Top 5 Most-Downloaded Papers, *Journal of the American College of Clinical Pharmacy* (for "To Tweet or Not to Tweet? A Primer on Social Media for Pharmacists") 2017

Editor's Picks / Editor's Choice Awards

- Editor's Pick Award, *Pharmacotherapy* (for "Role of Lipoprotein(a) in Atherosclerotic Cardiovascular Disease: A Review of Current and Emerging Therapies") 2025
- Top 10 Research Impact Article, *Journal of the American Heart Association* 2023

(for “Interleukin-1 Blockade Inhibits the Acute Inflammatory Response in Patients With ST-Segment-Elevation Myocardial Infarction”)

- Top 100 Paper, *Journal of the American College of Cardiology* 2021
(for “Systolic Blood Pressure Time in Target Range and Cardiovascular Outcomes in Patients With Hypertension”)
- Editor’s Pick for the May Issue, *Journal of Cardiovascular Pharmacology* 2019
(for “Cardiovascular Considerations in Treating Patients with COVID-19”)

Best Poster Awards

- 1st Place, ACCP Ambulatory Care Practice & Research Network, ACCP Virtual Poster Symposium 2024
(for “Comparison of Prescribing Rates for SGLT2 Inhibitors and GLP1 Receptor Agonists Among Primary Care Clinics with and Without Embedded Pharmacists”)
- 1st Place, ACCP Ambulatory Care Practice & Research Network, ACCP Virtual Poster Symposium 2021
(for “Survey of CDC-recognized community pharmacies providing the National Diabetes Prevention Program”)
- 2nd Place, ACCP Ambulatory Care Practice & Research Network, ACCP Virtual Poster Symposium 2019
(for “Practice Patterns for Addressing LDL-Cholesterol Levels Below 40 in Patients Receiving Statin Therapy”)
- Honorable Mention (Outcomes Research), American College of Cardiology Scientific Sessions 2017
(for “Comparison of a Pharmacist-Physician Collaborative Care Model to Standard Care on the Time to Reach Goal Blood Pressure for Patients with Hypertension”)
- 1st Place, ACCP Ambulatory Care Practice & Research Network, ACCP Annual Meeting 2016
(for “Pharmacist-physician collaborative care model vs. standard card: assessing time to blood pressure goal”)
- 1st Place, Third Annual Jewell and Carl F. Emswiler Interprofessional Symposium 2015
(for “Pharmacist Physician Collaboration to Improve Blood Pressure Control in an Inner-City Safety-Net Clinic”)

Institutional (School/University) Awards

Excellence in Service Award, VCU School of Pharmacy	2021
AACP Lawrence C. Weaver Transformative Community Service Award (VCU School of Pharmacy)	2015
C. Peter Magrath University Community Engagement Award (VCU)	2014
Outstanding Preceptor Award, VCU School of Pharmacy	2013

Personal Achievements

1 st Degree Black Belt (1 st Dan), Taekwondo, Grandmaster Dong’s Martial Arts, Richmond, VA	2025
• Current ranking: 1st Dan, 4th Star working toward 2nd Degree Black Belt	

RESEARCH FUNDING

Current Funding

SCAN! (Skin Cancer Awareness Now!) Community Pharmacy Study
 Sponsor: American Cancer Society (RSG-21-022-01-CPPB); subaward to VCU as study site
 Role: Co-Investigator (PI, Kimberly Kelly, PhD, University of Tennessee Health Science Center)
 Dates: January 2026 – August 2026

Amount: \$25,000

Characterization of First-Generation Pharmacy Student Experiences: A Multi-School Qualitative Study

Sponsor: VCU First-Generation and Student Success and Research Center

Role: Co-Investigator (PI, Cait Gibson, PharmD, VCU School of Pharmacy)

Dates: June 2025 – August 2026

Amount: \$7,500

Prognostic Value of Systolic Blood Pressure Time in Target Range as an Alternative Quality Metric

Sponsor: VCU's CTSA (UM1TR004360) and the CCTR VCU Endowment Fund

Role: **Principal Investigator**

Dates: August 2024 – July 2026

Amount: \$115,000

Completed Funding

Translation of Evidence-Based Diabetes Care into Clinical Practice Across a Large Medical Group

Sponsor: Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC (Investigator-Initiated)

Role: **Principal Investigator**

Dates: April 2022 – March 2023

Amount: \$200,813

Medical oncologists' knowledge, comfort level, and ownership of the responsibility for managing hyperglycemia in cancer patients undergoing chemotherapy

Sponsor: New Investigator Award, American Association of Colleges of Pharmacy

Role: Co-Investigator (PI, Teresa Salgado, PhD, VCU School of Pharmacy)

Dates: March 2022 – February 2023

Amount: \$10,000

Virginia Medicaid MCO Value-Based Payment Pilot for the National Diabetes Prevention Program

Sponsor: Virginia Department of Health

Role: **Principal Investigator**

Dates: September 2021 – June 2023

Amount: \$32,500

A multifaceted adaptive mobile application to promote self-management and improve outcomes in heart failure

Sponsor: NIH (NIA): R01AG062582; subaward to VCU as study site

Role: **Site Principal Investigator** (PI, Michael Dorsch, PharmD, University of Michigan College of Pharmacy)

Dates: April 2020 – April 2023

Amount: \$35,569

Interprofessional Strategies to Improve Diabetes & Cardiovascular Disease in Underserved Areas

Sponsor: Virginia Department of Health (CDC-RFA-DP-18-1817)

Role: **Principal Investigator**

Dates: October 2018 – September 2023

Amount: \$1,262,290

Effects of IL-1 Blockade on Exercise Capacity in Patients with Recently Decompensated Systolic Heart Failure

Sponsor: NIH (NHLBI): R61HL139943

Role: Co-Investigator (PI, Ben Van Tassell, PharmD, VCU School of Pharmacy)

Dates: July 2018 – June 2023

Amount: \$2,700,048

Using 24-hour ABPM to examine the association between BP and cognitive impairment among African Americans

Sponsor: Center for Healthy Aging Behaviors and Longitudinal Investigations Pilot

Role: **Co-Principal Investigator**

Dates: July 2021 – June 2022

Amount: \$22,973

The association of ambulatory blood pressure phenotypes with cognition in community-dwelling older adults

Sponsor: VCU CCTR Endowment Fund CTSA (UL1TR002649)

Role: **Co-Principal Investigator**

Dates: February 2021 – July 2022

Amount: \$49,782

Factors affecting job satisfaction in board-certified pharmacists

Sponsor: Board of Pharmacy Specialties Seed Grant

Role: Co-Investigator (PI, Lauren Pamulapati, PharmD, VCU School of Pharmacy)

Dates: November 2020 – November 2022

Amount: \$5,000

Implementation and Evaluation of a 24-hour ABPM Service in Community Pharmacies

Sponsor: Community Pharmacy Foundation Grant #71756

Role: **Principal Investigator**

Dates: February 2019 – February 2020

Amount: \$47,165

A Pharmacist-driven Continuous Glucose Monitoring Program for Diabetes Management in an Uninsured Population

Sponsor: Virginia Pharmacists Association Foundation

Role: Co-Investigator/Mentor (PI, Jamie Cook, PharmD, VCU School of Pharmacy)

Dates: January 2017 – December 2019

Amount: \$2,500

Unsaturated Fatty Acids Enriched Diet to Improve Cardiorespiratory Fitness in Obese Patients: A Feasibility Study

Sponsor: VCU Department of Internal Medicine Pilot Project Grant Program

Role: Co-Investigator (PI, Salvatore Carbone, PhD, VCU School of Medicine)

Dates: January 2017 – December 2018

Amount: \$20,000

Treatment of Diabetes in Patients with Systolic Heart Failure: Canagliflozin versus Sitagliptin

Sponsor: Janssen Therapeutics (Investigator-Initiated)

Role: Co-Investigator (PI, Antonio Abbate, MD, PhD, VCU School of Medicine)

Dates: October 2016 – October 2018

Amount: \$809,347

Primary Care Training Collaborative Educational Program: A Retooling Program for the Future

Sponsor: Martin Health Foundation

Role: **Co-Principal Investigator**

Dates: March 2015 – March 2019

Amount: \$99,749

An Interprofessional Intervention with Behavioral Health and Pharmacy Trainees to Reduce Smoking Rates in a Latino Population at a Free Health Clinic

Sponsor: VCU Community Engagement Grant

Role: Co-Investigator (PI, John Bucheit, PharmD, VCU School of Pharmacy)

Dates: January 2017 – January 2019

Amount: \$17,224

SGLT2 Inhibitors in Diabetic Patients with Heart Failure with Reduced Ejection Fraction

Sponsor: AHA Mentored Clinical and Population Research Award

Role: Co-Investigator (PI, Salvatore Carbone, PhD, VCU School of Medicine)

Dates: January 2016 – January 2018

Amount: \$154,000

Interleukin-1 Blockade in Heart Failure with Preserved Ejection Fraction (DHART2)

Sponsor: NIH (NHLBI): R34HL118348

Role: Co-Investigator (PI, Antonio Abbate, MD, PhD, VCU School of Medicine)

Dates: January 2014 – January 2016

Amount: \$681,103

Clinical Pharmacist Understanding of the 2013 ACC/AHA Cholesterol Guideline

Sponsor: ACCP Cardiology Practice & Research Network Grant

Role: Co-Investigator (PI, John Bucheit, PharmD, VCU School of Pharmacy)

Dates: October 2016 – September 2017

Amount: \$5,000

Nighttime Dosing of Amlodipine versus Lisinopril in Non-Dipping African Americans

Sponsor: New Investigator Award, American Association of Colleges of Pharmacy

Role: **Principal Investigator**

Dates: 2015 – 2016

Amount: \$10,000

iForum Rx: An Online Journal Club for Ambulatory Care Practitioners

Sponsor: ACCP Ambulatory Care Practice & Research Network Innovation Grant

Role: Co-Investigator (PI, Stuart Haines, PharmD, University of Maryland School of Pharmacy)

Dates: 2013 – 2014

Amount: \$2,000

Use of Video Recorded Clinic Visits to Improve Assessment of Student Pharmacist Clinical Interviewing Skills

Sponsor: VCU Center for Teaching Excellence Small Grant Program

Role: **Principal Investigator**

Dates: 2012 – 2013

Amount: \$800

PEER-REVIEWED PUBLICATIONS (n = 198) *mentee

Bibliometric Indicators (metrics accessed July 31, 2026)

Indicator	Web of Science	Scopus	Google Scholar
<i>h</i> -index	39	45	48

Total citations	8,644	10,603	12,236
-----------------	-------	--------	--------

Clinical Practice Guidelines, Scientific Statements, Position Papers

1. Kittleson MM, Panjrath GS, Bates K, Breathett KK, **Dixon DL**, Januzzi JL Jr, Mohammed SF. Management of Heart Failure With Preserved Ejection Fraction: 2026 ACC Expert Consensus Decision Pathway: A Report of the American College of Cardiology Solution Set Oversight Committee. *J Am Coll Cardiol*. 2026 Jul 23:S0735-1097(26)06875-0. doi: 10.1016/j.jacc.2026.06.018. Epub ahead of print. PMID: 42494134. **Role: Member, Writing Committee**
2. Writing Committee Members; Ndumele CE, Rodriguez F, **Dixon DL**, Khan SS, Mukherjee D, Bajaj M, Bangalore S, Bozkurt B, Breathett K, Clarke SL, de Boer IH, Ellison DH, Evangelista LS, Heffron SP, Kazi DS, Kulshreshtha A, Lingvay I, Low Wang CC, Mercado CA, Morton JM, Neeland IJ, Pagidipati N, Powell-Wiley TM, Rangaswami J, Rao G, Reza N, Saeed A, St Peter W, Starks JB, Sterling M, Talbot AW, Tran AH, Tuttle KR, VanWagner LB, Vest AR, Virani SS. 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*. 2026 Jun 9. doi: 10.1161/CIR.0000000000001453. Epub ahead of print. PMID: 42263157. Simultaneously published in *J Am Coll Cardiol*. 2026 Jun 9;87(22S):e1889-e2007. doi: 10.1016/j.jacc.2026.03.056. PMID: 42265997. **Role: Member, Writing Committee and Leadership Team**
3. Writing Committee Members; Blumenthal RS, Morris PB, Gaudino M, Johnson HM, Anderson TS, Bittner VA, Blankstein R, Brewer LC, Cho L, de Ferranti SD, Gianos E, Gluckman TJ, Gradney KF, Isadinso I, Lloyd-Jones DM, Marrs JC, Martin SS, McLain KH, Mehta LS, Mora S, Mulugeta WM, Natarajan P, Navar AM, Orringer CE, Polonsky TS, Reynolds HR, Saseen JJ, Shapiro MD, Soffer DE, Tynes SA, Villavaso CD, Virani SS, Wilkins JT; **Peer Review Committee Members [...Dixon DL]**. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*. 2026 Mar 13. doi: 10.1161/CIR.0000000000001423. Epub ahead of print. PMID: 41824552. **Role: Collaborator and Member of the Peer Review Committee**
4. American Diabetes Association Professional Practice Committee for Diabetes [...**Dixon DL**]. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2026. *Diabetes Care*. 2026 Jan 1;49(Supplement_1):S216-S245. doi: 10.2337/dc26-S010. PMID: 41358899; PMCID: PMC12690187. **Role: Designated Subject Matter Expert**
5. American Diabetes Association Professional Practice Committee for Diabetes [...**Dixon DL**]. Summary of Revisions: Standards of Care in Diabetes-2026. *Diabetes Care*. 2026 Jan 1;49(1 Suppl 1):S6-S12. doi: 10.2337/dc26-SREV. PMID: 41358896; PMCID: PMC12690167. **Role: Designated Subject Matter Expert**
6. American Diabetes Association Professional Practice Committee for Diabetes [...**Dixon DL**]. Introduction and Methodology: Standards of Care in Diabetes-2026. *Diabetes Care*. 2026 Jan 1;49(Supplement_1):S1-S5. doi: 10.2337/dc26-SINT. PMID: 41358883; PMCID: PMC12690168. **Role: Designated Subject Matter Expert**
7. **Dixon DL**, Buckley LF, Aljadeed R, Baker WL, Barreto JN, Greer SC, Yang AY, Laizure SC, Leino AD, MacLaren R, Moore D, Nahata MC, Ng TMH, Nguyen E. The Clinical Pharmacist as Principal Investigator – 2026. *J Am Coll Clin Pharm*. 2025 Nov 27; doi.org/10.1002/jac5.70143. Official American College of Clinical Pharmacy Commentary. **Role: Chair, Writing Committee**
8. Cheeley MK, Kirkpatrick CF, Brown EE, **Dixon DL**, Gunter H, Osborn DS, Wilkinson MJ. Multidisciplinary teams in clinical lipidology and cardiometabolic care: A National Lipid Association Expert Clinical Review. *J Clin*

Lipidol. 2025 May 29:S1933-2874(25)00283-1. doi: 10.1016/j.jacl.2025.05.002. Epub ahead of print. PMID: 40483195. **Role: Member, Writing Committee**

9. Bittner V, Linnebur SA, **Dixon DL**, Forman DE, Green AR, Jacobson TA, Orkaby AR, Saseen JJ, Virani SS. Managing hypercholesterolemia in adults older than 75 years without a history of atherosclerotic cardiovascular disease: An Expert Clinical Consensus from the National Lipid Association and the American Geriatrics Society. *J Clin Lipidol*. 2025 Mar-Apr;19(2):215-237. doi: 10.1016/j.jacl.2024.09.005. Epub 2025 Apr 10. PMID: 40250966. *J Am Geriatr Soc*. 2025 Jun;73(6):1674-1696. doi: 10.1111/jgs.19398. Epub 2025 Apr 10. PMID: 40207842. **Role: Member, Writing Committee**
10. Soffer DE, Marston NA, Maki KC, Jacobson TA, Bittner VA, Peña JM, Thanassoulis G, Martin SS, Kirkpatrick CF, Virani SS, **Dixon DL**, Ballantyne CM, Remaley AT. Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: An expert clinical consensus from the National Lipid Association. *J Clin Lipidol*. 2024 Sep 5:S1933-2874(24)00240-X. doi: 10.1016/j.jacl.2024.08.013. Epub ahead of print. PMID: 39256087. **Role: Member, Writing Committee**
11. Agarwala A, **Dixon DL**, Gianos E, Kirkpatrick CF, Michos ED, Satish P, Birtcher KK, Braun LT, Pillai P, Watson K, Wild R, Mehta LS. Dyslipidemia management in women of reproductive potential: An expert clinical consensus from the National Lipid Association. *J Clin Lipidol*. 2024 May 30:S1933-2874(24)00188-0. doi: 10.1016/j.jacl.2024.05.005. Epub ahead of print. PMID: 38824114. **Role: Member, Writing Committee**
12. Bays HE, Kirkpatrick C, Maki KC, Toth PP, Morgan RT, Tondt J, Christensen SM, **Dixon D**, Jacobson TA. Obesity, dyslipidemia, and cardiovascular disease: A joint expert review from the Obesity Medicine Association and the National Lipid Association 2024. *J Clin Lipidol*. 2024 Apr 18:S1933-2874(24)00048-5. doi: 10.1016/j.jacl.2024.04.001. Epub ahead of print. PMID: 38664184. Simultaneously published in *Obes Pillars*. 2024 Mar 12;10:100108. doi: 10.1016/j.obpill.2024.100108. PMID: 38706496; PMCID: PMC11066689. **Role: Member, Writing Committee**
13. Koschinsky ML, Bajaj A, Boffa MB, **Dixon DL**, Ferdinand KC, Gidding SS, Gill EA, Jacobson TA, Michos ED, Safarova MS, Soffer DE, Taub PR, Wilkinson MJ, Wilson DP, Ballantyne CM. A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice. *J Clin Lipidol*. 2024 Mar 29:S1933-2874(24)00033-3. doi: 10.1016/j.jacl.2024.03.001. Epub ahead of print. PMID: 38565461. **Role: Member, Writing Committee**
14. Writing Committee Members; Isselbacher EM, Preventza O, Hamilton Black J 3rd, Augoustides JG, Beck AW, Bolen MA, Braverman AC, Bray BE, Brown-Zimmerman MM, Chen EP, Collins TJ, DeAnda A Jr, Fanola CL, Girardi LN, Hicks CW, Hui DS, Schuyler Jones W, Kalahasti V, Kim KM, Milewicz DM, Oderich GS, Ogbechie L, Promes SB, Ross EG, Schermerhorn ML, Singleton Times S, Tseng EE, Wang GJ, Woo YJ; Peer Review Committee Members; Faxon DP, Upchurch GR Jr, Aday AW, Azizzadeh A, Boisen M, Hawkins B, Kramer CM, Luc JGY, MacGillivray TE, Malaisrie SC, Osteen K, Patel HJ, Patel PJ, Popescu WM, Rodriguez E, Sorber R, Tsao PS, Santos Volgman A; AHA/ACC Joint Committee Members; Beckman JA, Otto CM, O'Gara PT, Armbruster A, Birtcher KK, de las Fuentes L, Deswal A, **Dixon DL**, Gorenek B, Haynes N, Hernandez AF, Joglar JA, Jones WS, Mark D, Mukherjee D, Palaniappan L, Piano MR, Rab T, Spatz ES, Tamis-Holland JE, Woo YJ. 2022 ACC/AHA guideline for the diagnosis and management of aortic disease: A report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. *J Thorac Cardiovasc Surg*. 2023 Nov;166(5):e182-e331. doi: 10.1016/j.jtcvs.2023.04.023. Epub 2023 Jun 28. PMID: 37389507; PMCID: PMC10784847. **Role: Collaborator**
15. Virani SS, Newby LK, Arnold SV, Bittner V, Brewer LC, Demeter SH, **Dixon DL**, Fearon WF, Hess B, Johnson HM, Kazi DS, Kolte D, Kumbhani DJ, LoFaso J, Mahtta D, Mark DB, Minissian M, Navar AM, Patel AR, Piano

- MR, Rodriguez F, Talbot AW, Taqueti VR, Thomas RJ, van Diepen S, Wiggins B, Williams MS. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. *Circulation*. 2023 Aug 29;148(9):e9-e119. doi: 10.1161/CIR.0000000000001168. Epub 2023 Jul 20. PMID: 37471501. Simultaneously published in *J Am Coll Cardiol*. 2023 Aug 29;82(9):833-955. doi: 10.1016/j.jacc.2023.04.003. Epub 2023 Jul 20. PMID: 37480922. **Role: Member, Writing Committee and Leadership Team**
16. Kittleson MM, Panjra GS, Amancherla K, Davis LL, Deswal A, **Dixon DL**, Januzzi JL Jr, Yancy CW. 2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. *J Am Coll Cardiol*. 2023 May 9;81(18):1835-1878. doi: 10.1016/j.jacc.2023.03.393. Epub 2023 Apr 19. PMID: 37137593. **Role: Member, Writing Committee**
 17. Virani SS, Aspry K, **Dixon DL**, Ferdinand KC, Heidenreich PA, Jackson EJ, Jacobson TA, McAlister JL, Neff DR, Gulati M, Ballantyne CM. The importance of low-density lipoprotein cholesterol measurement and control as performance measures: A joint Clinical Perspective from the National Lipid Association and the American Society for Preventive Cardiology. *J Clin Lipidol*. 2023 Mar-Apr;17(2):208-218. doi: 10.1016/j.jacl.2023.02.003. Epub 2023 Feb 27. PMID: 36965958, *Am J Prev Cardiol*. 2023 Feb 27;13:100472. doi: 10.1016/j.ajpc.2023.100472. PMID: 36970638. **Role: Member, Writing Committee**
 18. **Dixon DL**, Harris IM, Aljadeed R, Anderson KC, Aycock A, Beavers C, Beckman EJ, Isaacs D, McCoy E, Sandler A, Saseen JJ, Singh S, Wagner J. Overview of Clinical Practice Guideline Development, Application to Pharmacy Practice, and Roles for Pharmacists. *J Am Coll Clin Pharm*. 2023;6(1):73-84. doi:10.1002/jac5.1743. **[White Paper]**
 19. Warden BA, Guyton JR, Kovacs AC, Durham JA, Jones LK, **Dixon DL**, Jacobson TA, Duell PB. Assessment and management of statin-associated muscle symptoms (SAMS): A clinical perspective from the National Lipid Association. *J Clin Lipidol*. 2023 Jan-Feb;17(1):19-39. doi:10.1016/j.jacl.2022.09.001. Epub 2022 Sep 11. PMID: 36115813. **Role: Member, Writing Committee**
 20. Cheeley MK, Saseen JJ, Agarwala A, Ravilla S, Ciffone N, Jacobson TA, **Dixon DL**, Maki KC. NLA scientific statement on statin intolerance: a new definition and key risk reduction in the statin intolerant patient. *J Clin Lipidol*. 2022 Jul-Aug;16(4):361-375. doi: 10.1016/j.jacl.2022.05.068. Epub 2022 Jun 9. PMID: 35718660. **Role: Member, Writing Committee**
 21. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nwacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW; ACC/AHA Joint Committee Members [...**Dixon DL**]. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*. 2022 May 3;145(18):e895-e1032. doi: 10.1161/CIR.0000000000001063. Simultaneously published in *J Card Fail*. 2022 May;28(5):e1-e167. doi: 10.1016/j.cardfail.2022.02.010. Epub 2022 Apr 1. PMID: 35378257. **Role: Collaborator**
 22. Writing Committee Members; Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP 3rd, Gentile F, Jneid H, Krieger EV, Mack M, McLeod C, O'Gara PT, Rigolin VH, Sundt TM 3rd, Thompson A, Toly C; ACC/AHA Joint Committee Members; O'Gara PT, Beckman JA, Levine GN, Al-Khatib SM, Armbruster A, Birtcher KK, Cigarroa J, Deswal A, **Dixon DL**, Fleisher LA, de las Fuentes L, Gentile F, Goldberger ZD, Gorenek B, Haynes N, Hernandez AF, Hlatky MA, Joglar JA, Jones WS, Marine JE, Mark D, Palaniappan L,

- Piano MR, Spatz ES, Tamis-Holland J, Wijeyesundera DN, Woo YJ. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *J Thorac Cardiovasc Surg*. 2021 Aug;162(2):e183-e353. doi: 10.1016/j.jtcvs.2021.04.002. Epub 2021 May 8. PMID: 33972115. **Role: Collaborator**
23. Writing Committee Members; Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P, Evanovich LL, Hung J, Joglar JA, Kantor P, Kimmelstiel C, Kittleson M, Link MS, Maron MS, Martinez MW, Miyake CY, Schaff HV, Semsarian C, Sorajja P; ACC/AHA Joint Committee Members; O'Gara PT, Beckman JA, Levine GN, Al-Khatib SM, Armbruster A, Birtcher KK, Cigarroa J, **Dixon DL**, de las Fuentes L, Deswal A, Fleisher LA, Gentile F, Goldberger ZD, Gorenek B, Haynes N, Hernandez AF, Hlatky MA, Joglar JA, Jones WS, Marine JE, Mark D, Palaniappan L, Piano MR, Tamis-Holland J, Wijeyesundera DN, Woo YJ. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *J Thorac Cardiovasc Surg*. 2021 Jul;162(1):e23-e106. doi: 10.1016/j.jtcvs.2021.04.001. Epub 2021 Apr 27. PMID: 33926766. **Role: Collaborator**
24. Robinson JG, Jayanna MB, Brown AS, Aspary K, Orringer C, Gill EA, Goldberg A, Jones LK, Maki K, **Dixon DL**, Saseen JJ, Soffer D. Enhancing the value of PCSK9 monoclonal antibodies by identifying patients most likely to benefit. A consensus statement from the National Lipid Association. *J Clin Lipidol*. 2019 Jul-Aug;13(4):525-537. doi: 10.1016/j.jacl.2019.05.005. Epub 2019 May 16. PMID: 31281070. **Role: Member, Writing Committee**
25. Sperling LS, Mechanick JI, Neeland IJ, Herrick CJ, Després JP, Ndumele CE, Vijayaraghavan K, Handelsman Y, Puckrein GA, Araneta MR, Blum QK, Collins KK, Cook S, Dhurandhar NV, **Dixon DL**, Egan BM, Ferdinand DP, Herman LM, Hessen SE, Jacobson TA, Pate RR, Ratner RE, Brinton EA, Forker AD, Ritzenthaler LL, Grundy SM. The CardioMetabolic Health Alliance: Working Toward a New Care Model for the Metabolic Syndrome. *J Am Coll Cardiol*. 2015 Sep 1;66(9):1050-67. doi: 10.1016/j.jacc.2015.06.1328. PMID: 26314534. **Role: Member, Writing Committee**
26. American College of Clinical Pharmacy, McBane SE, Dopp AL, Abe A, Benavides S, Chester EA, **Dixon DL**, Dunn M, Johnson MD, Nigro SJ, Rothrock-Christian T, Schwartz AH, Thrasher K, Walker S. Collaborative drug therapy management and comprehensive medication management-2015. *Pharmacotherapy*. 2015 Apr;35(4):e39-50. doi: 10.1002/phar.1563. PMID: 25884536. **Role: Member, Writing Committee**

Peer-Reviewed Original Research and Meta-Analyses

- Salgado TM, Amayreh R, Alshahawey M, Musselman KT, Buffington TM, Hyder H, Jones RM, **Dixon DL**. Contextual Factors Affecting SGLT2 Inhibitors and GLP-1 Receptor Agonists Prescribing in Primary Care: An Application of the Consolidated Framework for Implementation Research. *J Am Coll Clin Pharm*. 2026 Aug;9(8):e70263. doi: 10.1002/jac5.70263. PMID: 42522049.
- Dixon DL**, Salgado TM, Robinson A, Carbone S, Wagner TD, Hyder H, Kirschner B, Musselman KT, Buffington TM, Sabo RT. A cross-sectional study of prescribing rates for SGLT2 inhibitors and GLP-1 receptor agonists among primary care clinics with and without embedded pharmacists. *J Am Pharm Assoc (2003)*. 2026 Mar 27;103106. doi: 10.1016/j.japh.2026.103106. Epub ahead of print. PMID: 41905685.
- *Sproule T, Sargent L, Price E, Mackiewicz M, Thacker L, **Dixon D**. Association Between ABPM Phenotypes and Cognitive Impairment in a Community-Dwelling, Older Adult Population Taking Antihypertensive Medication: A Pilot Study. *Am J Hypertens*. 2026 Mar 1;39(3):367-371. doi: 10.1093/ajh/hpaf188. PMID: 40972083.

4. Dorsch MP, Ali MS, Krambrink A, Kolenic G, Ganai S, Arzac J, Zhang X, Greer KM, Shah AJ, Cowger JA, Ewald G, Rodgers JE, **Dixon DL**, Koelling TM, Hummel SL. The ManageHF Just-in-Time Adaptive Mobile App Interventions to Promote Self-Management and Improve Outcomes in Heart Failure: Randomized Controlled Trial. *JMIR Mhealth Uhealth*. 2026 Jul 28;14:e74121. doi: 10.2196/74121. PMID: 42520258.
5. *Bohmke NJ, Barton B, Wiecek P, Rodriguez-Miguel P, **Dixon DL**, Kim Y, Carbone S, Kirkman DL. Chronobiology of meal timing in early-stage hypertension: a controlled feeding pilot study investigating the effects on renal and vascular function. *J Appl Physiol*. 2025 Dec 11. doi: 10.1152/japplphysiol.00443.2025. Epub ahead of print. PMID: 41379631.
6. Pontinha VM, **Dixon DL**, Carroll NV, Farris KB, Holdford DA. Examining the association between medication adherence trajectories and disease-specific clinical outcomes: An analysis focusing on the drug classes included in Part D quality bonus payments. *J Manag Care Spec Pharm*. 2025 Nov;31(11):1177-1188. doi: 10.18553/jmcp.2025.31.11.1177. PMID: 41171062; PMCID: PMC12577725.
7. Backes JM, Beavers CJ, **Dixon DL**, Gibson CA, Hilleman DE, Malesker MA, Saseen JJ, Dilsaver DB. Assessing pharmacists' knowledge and practices involving dietary supplement omega-3 fatty acids. *J Clin Lipidol*. 2025 Sep 12:S1933-2874(25)00393-9. doi: 10.1016/j.jacl.2025.09.007. Epub ahead of print. PMID: 41073239.
8. Ortega-Paz L, Talasaz AH, Sadeghipour P, Rashedi S, Connors JM, Angiolillo DJ, Cavallari LH, Jimenez D, Bastidas G, Lorenzi E, Berry LR, Hills T, McAuley DF, Shah T, Lansky AJ, Deepti S, Gaitán-Duarte HG, Potpara TS, Galli M, **Dixon DL**, Piazza G, Lip GYH, Mehran R, Libby P, Krumholz HM, Bikdeli B. Safety and effectiveness of statins in hospitalized patients with COVID-19: Systematic review and collaborative meta-analysis of randomized controlled trials. *Thromb Res*. 2025 Sep 20;255:109484. doi: 10.1016/j.thromres.2025.109484. Epub ahead of print. PMID: 40992230.
9. Alsakaker AA, Alfayez JS, Alsalamah JA, Alzughibi LS, Anaam MS, **Dixon DL**, Khan RA, Alhomoud IS. ChatGPT: Pharmacy students' perceptions, current use trends, ethical awareness, standards of ethics, prospects and recommendations for future use. *Curr Pharm Teach Learn*. 2025 Jun 13;17(10):102382. doi: 10.1016/j.cptl.2025.102382. Epub ahead of print. PMID: 40516239.
10. Kelly MS, Jeminiwa RN, Gohar F, Fanous M, Ramirez P, **Dixon DL**. Evaluation of lipid-lowering therapy in patients with elevated lipoprotein(a) levels. *J Clin Lipidol*. 2025 May 8:S1933-2874(25)00277-6. doi: 10.1016/j.jacl.2025.04.200. Epub ahead of print. PMID: 40467440.
11. *Wagner TD, **Dixon DL**, Shin Y, Dozmorov M, Musselman KT, Buffington TM, Hyder H, Kirschner B, Jones RM, Salgado TM. Impact of pharmacist-physician collaborative care on hemoglobin A1c and blood pressure quality measure achievement in primary care. *J Manag Care Spec Pharm*. 2025 Jun;31(6):565-577. doi: 10.18553/jmcp.2025.31.6.565. PMID: 40443003; PMCID: PMC12123200.
12. *Alebna PL, Ambrosio M, Martin M, Martey S, Spitz JA, Sharma G, Van Tassell B, **Dixon DL**, Hundley WG, Salloum FN, Mehta A. Association of Lipoprotein(a) with cardiovascular events among individuals with autoimmune conditions. *Atherosclerosis*. 2025 May 13;406:119244. doi: 10.1016/j.atherosclerosis.2025.119244. Epub ahead of print. PMID: 40398292.
13. Pontinha VM, Patterson JA, **Dixon DL**, Carroll NV, Mays D, Farris KB, Holdford DA. Investigating the Time-Varying Nature of Medication Adherence Predictors: An Experimental Approach Using Andersen's Behavioral Model of Health Services Use. *Pharmacy (Basel)*. 2025 Apr 9;13(2):53. doi: 10.3390/pharmacy13020053. PMID: 40278536; PMCID: PMC12030111.

14. **Dixon DL**, Salgado TM, Robinson A, Carbone S, Wagner TD, Hyder H, Kirschner B, Musselman KT, Buffington TM, Sabo RT. Prescribing Patterns of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Patients With Type 2 Diabetes at Cardiology, Endocrinology, and Primary Care Visits. *Mayo Clin Proc.* 2025 Apr;100(4):647-656. doi: 10.1016/j.mayocp.2024.08.026. Epub 2025 Mar 7. PMID: 40057872.
15. Winship JM, Mackiewicz M, Babar M, **Dixon DL**, Price ET, Sargent LJ. "I Have Come Because I See You Care About Me": Recruiting Older Black Americans for Genomic Research. *Ethn Dis.* 2024 Oct 22;34(4):185-191. doi: 10.18865/EthnDis-2023-75. PMID: 39463816; PMCID: PMC11500639.
16. *Alebna PM, Hap CY, Ambrosio M, Kong G, Cyrus JW, Harley K, Kang L, Small AM, Chevli P, Bhatia H, Chew N, Salloum FN, **Dixon DL**, Abbate A, Natarajan P, Shapiro MD, Mehta A. Association of Lipoprotein(a) With Major Adverse Cardiovascular Events Across hs-CRP: A Systematic Review and Meta-Analysis. *JACC: Advances.* 2024;3(12). doi: 10.1016/j.jacadv.2024.101409
17. Salgado TM, Radwan RM, Hickey Zacholski E, Mackler E, Buffington TM, Musselman KT, Irvin WJ Jr, Perkins JM, Le TN, **Dixon DL**, Farris KB, Sheppard VB, Jones RM. Oncologists' responsibility, comfort, and knowledge managing hyperglycemia in patients with cancer undergoing chemotherapy: a cross-sectional study. *Support Care Cancer.* 2023 Jul 8;31(8):450. doi: 10.1007/s00520-023-07927-9. PMID: 37421495.
18. Fox J, Bond R, Matulewicz AT, Gibson CM, Sanders K, **Dixon DL**. Exploring the Impact of Generation Status on Pharmacy Admissions: A Comparative Study of First-Generation and Continuing-Generation College Students. *Am J Pharm Educ.* 2024 Sep;88(9):101258. doi: 10.1016/j.ajpe.2024.101258. Epub 2024 Jul 31. PMID: 39094973.
19. Hughes J, Advancing Pharmacist Payment Parity Workgroup [...**Dixon DL**]. State of the Union: A review of state-based laws and regulations supporting pharmacist payment for clinical services. *J Am Coll Clin Pharm.* 2024; 7(9): 908-925. doi:10.1002/jac5.2008
20. Salgado TM, Birari PB, Alshahawey M, Hickey Zacholski E, Mackler E, Buffington TM, Musselman KT, Irvin WJ Jr, Perkins JM, Le TN, **Dixon DL**, Farris KB, Sheppard VB, Jones RM. Optimal hyperglycemia thresholds in patients undergoing chemotherapy: a cross-sectional study of oncologists' practices. *Support Care Cancer.* 2024 Aug 1;32(8):563. doi: 10.1007/s00520-024-08756-0. PMID: 39088060; PMCID: PMC11294379.
21. Sisson EM, Pamulapati LG, Bucheit JD, Zimmerman KM, **Dixon DL**, Holdford DA, Salgado TM. Integrating real-world skills and diabetes lifestyle coach training into a revised health promotion and communications course. *Curr Pharm Teach Learn.* 2024 Apr 16:S1877-1297(24)00017-0. doi: 10.1016/j.cptl.2024.01.002. Epub ahead of print. PMID: 38631946.
22. Nguyen DQ, Keshvani N, Chandra A, Alebna PL, **Dixon DL**, Shapiro MD, Michos ED, Sperling LS, Pandey A, Mehta A. Temporal trends and racial/ethnic- and sex-differences in LDL cholesterol control among US adults with self-reported atherosclerotic cardiovascular disease. *Am J Prev Cardiol.* 2024 Apr 15;18:100673. doi: 10.1016/j.ajpc.2024.100673. PMID: 38681067; PMCID: PMC11046243.
23. *Makawi AT, Tawfik YMK, **Dixon DL**, McMahon GM, Buckley LF. Expanding the Impact of SGLT2 Inhibitors in Chronic Kidney Disease. *Am J Nephrol.* 2024 Feb 28:1-4. doi: 10.1159/000536540. Epub ahead of print. PMID: 38417403.
24. *Alhomoud IS, *Cook E, *Patel D, Brown R, **Dixon DL**. Effect of Pharmacist Interventions on the Management of Overweight and Obesity: A Systematic Review. *J Am Pharm Assoc (2003).* 2024 Feb 26:102058. doi: 10.1016/j.japh.2024.102058. Epub ahead of print. PMID: 38417740.

25. *Zbyrak V, Radwan RM, Salgado TM, **Dixon DL**, Sisson EM, Pamulapati LG. Job satisfaction among board-certified pharmacists in Virginia. *J Am Pharm Assoc* (2003). 2024 Jan-Feb;64(1):126-132. doi: 10.1016/j.japh.2023.09.010. Epub 2023 Sep 28. PMID: 37774836.
26. *Pontinha VM, Patterson JA, **Dixon DL**, Carroll NV, Mays D, Barnes A, Farris KB, Holdford DA. Longitudinal medication adherence group-based trajectories of aging adults in the US: A retrospective analysis using monthly proportion of days covered calculations. *Res Social Adm Pharm*. 2023 Dec 27:S1551-7411(23)00500-4. doi: 10.1016/j.sapharm.2023.12.008. Epub ahead of print. PMID: 38176956.
27. Sargent L, Zimmerman KM, Mohammed A, Barrett MJ, Nawaz H, Wyman-Chick K, Mackiewicz M, Roman Y, Slattum P, Russell S, **Dixon DL**, Lageman SK, Hobgood S, Thacker LR, Price ET. Low-Income Older Adults' Vulnerability to Anticholinergic Medication-Associated Frailty. *Drugs Aging*. 2023 Dec;40(12):1123-1131. doi: 10.1007/s40266-023-01069-7. Epub 2023 Oct 19. PMID: 37856064.
28. Mehta A, Lee TB, Alebna P, Grandhi GR, **Dixon DL**, Salloum FN, Sanyal AJ, Siddiqui MS. Discordant association of nonalcoholic fatty liver disease with lipoprotein(a) and markers of atherogenic dyslipidemia. *J Clin Lipidol*. 2023 Sep 21:S1933-2874(23)00262-3. doi: 10.1016/j.jacl.2023.09.003. Epub ahead of print. PMID: 37957050.
29. **Dixon DL**, Johnston K, Patterson J, Marra CA, Tsuyuki RT. Cost-Effectiveness of Pharmacist Prescribing for Managing Hypertension in the United States. *JAMA Netw Open*. 2023 Nov 1;6(11):e2341408. doi: 10.1001/jamanetworkopen.2023.41408. PMID: 37921763.
30. Romeo FJ, Del Buono MG, Aguilar-Gallardo JS, Lorente-Ros M, Damonte JI, Chiabrando JG, **Dixon DL**, Biondi-Zoccai G, Abbate A, Carbone S. Cardiac remodeling with SGLT2 inhibitors in heart failure with reduced ejection fraction. *Minerva Cardiol Angiol*. 2023 Jun 13. doi: 10.23736/S2724-5683.22.06207-X. Epub ahead of print. PMID: 37310155.
31. Talasaz A, Sculthorpe R, Pak M, Lipinski M, Roberts C, Markley R, Trankle C, Canada JM, Wohlford GF, Golino M, **Dixon DL**, Van Tassell B, Abbate A. Comparison of safety and biological efficacy of anakinra (Kineret®) dispensed in polycarbonate plastic versus borosilicate glass syringes: a patient-level analysis of VCUART2 and VCUART3 clinical trials. *J Pharmacol Exp Ther*. 2023 Mar 3:JPET-AR-2022-001404. doi: 10.1124/jpet.122.001404. Epub ahead of print. PMID: 36868827.
32. Tawfik YMK, Van Tassell BW, **Dixon DL**, Baker WL, Fanikos J, Buckley LF. Effects of Intensive Systolic Blood Pressure Lowering on End-Stage Kidney Disease and Kidney Function Decline in Adults With Type 2 Diabetes Mellitus and Cardiovascular Risk Factors: A Post Hoc Analysis of ACCORD-BP and SPRINT. *Diabetes Care*. 2023 Apr 1;46(4):868-873. doi: 10.2337/dc22-2040. PMID: 36787937.
33. Buckley LF, Baker WL, Van Tassell BW, Cohen JB, Alkhezi O, Bress AP, **Dixon DL**. Systolic Blood Pressure Time in Target Range and Major Adverse Kidney and Cardiovascular Events. *Hypertension*. 2023 Feb;80(2):305-313. doi: 10.1161/HYPERTENSIONAHA.122.20141. Epub 2022 Oct 18. PMID: 36254738.
 - **Editorial:** Schlaich MP. Time in Target Range: The Future of Assessing Adequacy of Blood Pressure Control? *Hypertension*. 2023 Feb;80(2):314-315. doi: 10.1161/HYPERTENSIONAHA.122.20355. Epub 2023 Jan 18. PMID: 36652530.
34. Van Tassell B, Mihalick V, Thomas G, Marawan A, Talasaz AH, Lu J, Kang L, Ladd A, Damonte JI, **Dixon DL**, Markley R, Turlington J, Federmann E, Del Buono MG, Biondi-Zoccai G, Canada JM, Arena R, Abbate A. Rationale and design of interleukin-1 blockade in recently decompensated heart failure (REDHART2): a

- randomized, double blind, placebo controlled, single center, phase 2 study. *J Transl Med.* 2022 Jun 15;20(1):270. doi: 10.1186/s12967-022-03466-9. PMID: 35706006.
35. *Tran C, Vo V, Taylor P, Koehn DA, Virani SS, **Dixon DL**. Adherence to lipid monitoring and its impact on treat intensification of LDL-C lowering therapies at an urban academic medical center. *J Clin Lipidol.* 2022 Jul-Aug;16(4):491-497. doi: 10.1016/j.jacl.2022.05.003. Epub 2022 May 11. PMID: 35610140.
 36. *Spence R, Sisson EM, **Dixon DL**. Survey of CDC-recognized community pharmacies providing the National Diabetes Prevention Program and impact of the COVID-19 pandemic on program delivery. *J Am Pharm Assoc* (2003). 2022 Sep-Oct;62(5):1581-1586. doi: 10.1016/j.japh.2022.03.020. Epub 2022 Mar 31. PMID: 35461779; PMCID: PMC8968123.
 37. *Billingsley HE, Canada JM, **Dixon DL**, Kirkman DL, Bohmke N, Rotelli B, Kadariya D, Markley R, Van Tassell BW, Celi FS, Abbate A, Carbone S. Midpoint of energy intake, non-fasting time and cardiorespiratory fitness in heart failure with Preserved ejection fraction and obesity. *Int J Cardiol.* 2022 May 15;355:23-27. doi: 10.1016/j.ijcard.2022.03.010. Epub 2022 Mar 9. PMID: 35276244
 38. *Radwan RM, Bentley JP, Patterson JA, **Dixon DL**, Salgado TM. Predictors of job satisfaction among pharmacists: A regional workforce survey. *Explor Res Clin Soc Pharm.* 2022 Mar 7;5:100124. doi: 10.1016/j.rcsop.2022.100124. PMID: 35478529.
 39. *Billingsley H, **Dixon D**, Yehya A, Carbone S, Abbate A. Sleeve Gastrectomy Reduces BMI and Pill Count in Patients With LVAD. *J Cardiovasc Pharmacol.* 2022 May 1;79(5):644-645. doi: 10.1097/FJC.0000000000001249. PMID: 35234737.
 40. Jay JS, Ijioma SC, Holdford DA, **Dixon DL**, Sisson EM, Patterson JA. The cost-effectiveness of pharmacist-physician collaborative care models vs usual care on time in target systolic blood pressure range in patients with hypertension: a payer perspective. *J Manag Care Spec Pharm.* 2021 Dec;27(12):1680-1690. doi: 10.18553/jmcp.2021.27.12.1680. PMID: 34818090.
 41. Zheutlin AR, Derington CG, King JB, Berchie RO, Herrick JS, **Dixon DL**, Cohen JB, Shimbo D, Kronish IM, Saseen JJ, Muntner P, Moran AE, Bress AP. Factors associated with antihypertensive monotherapy among US adults with treated hypertension and uncontrolled blood pressure overall and by race/ethnicity, National Health and Nutrition Examination Survey 2013-2018. *Am Heart J.* 2022 Jun;248:150-159. doi: 10.1016/j.ahj.2021.10.184. Epub 2021 Oct 16. PMID: 34662571
 42. Talasaz AH, Ho AJ, Bhatti F, Koenig RA, **Dixon DL**, Baker WL, Van Tassell BW. Meta-analysis of clinical outcomes of PCSK9 modulators in patients with established ASCVD. *Pharmacotherapy.* 2021 Dec;41(12):1009-1023. doi: 10.1002/phar.2635. Epub 2021 Oct 30. PMID: 34657313.
 43. **Dixon DL**, Baker WL, Buckley LF, Salgado TM, Van Tassell BW, Carter BL. Effect of a Physician/Pharmacist Collaborative Care Model on Time in Target Range for Systolic Blood Pressure: Post Hoc Analysis of the CAPTION Trial. *Hypertension.* 2021 Sep;78(4):966-972. doi: 10.1161/HYPERTENSIONAHA.121.17873. Epub 2021 Aug 15. PMID: 34397278.
 44. Shrestha DB, Budhathoki P, Sedhai YR, Baniya R, Cable CA, Kashiouris MG, **Dixon DL**, Kidd JM, Adhikari Y, Marasini A, Bhandari S. Patiromer and Sodium Zirconium Cyclosilicate in Treatment of Hyperkalemia: A Systematic Review and Meta-Analysis. *Curr Ther Res Clin Exp.* 2021 Jul 5;95:100635. doi: 10.1016/j.curtheres.2021.100635. PMID: 34367383

45. **Dixon DL**, Baker WL. Long-term Association of Altmetric Attention Scores With Citations in Selected Major Pharmacy Journals. *Am J Pharm Educ*. 2022 Feb;86(2):ajpe8606. doi: 10.5688/ajpe8606. Epub 2021 Jul 22. PMID: 34301563.
46. **Dixon DL**, Billingsley HE, Canada JM, Trankle CR, Kadariya D, Cooke R, Hart L, Van Tassell B, Abbate A, Carbone S. Effect of Canagliflozin Compared With Sitagliptin on Serum Lipids in Patients with Type 2 Diabetes Mellitus and Heart Failure with Reduced Ejection Fraction: A Post-Hoc Analysis of the CANA-HF Study. *J Cardiovasc Pharmacol*. 2021 Sep 1;78(3):407-410. doi: 10.1097/FJC.0000000000001083. PMID: 34132690
47. **Dixon DL**, Sobieraj DM, Brown RE, Koenig RA, Wagner M, Baker WL. A Bibliometric Analysis of Peer-Reviewed Journal Publications of Pharmacy Practice Department Chairs. *Am J Pharm Educ*. 2021 Sep;85(8):8481. doi: 10.5688/ajpe8481. Epub 2021 May 4. PMID: 34615625; PMCID: PMC8500282.
48. Billingsley HE, **Dixon DL**, Canada JM, Kirkman DL, Rotelli B, Kadariya D, Bohmke N, Markley R, Van Tassell BW, Celi FS, Abbate A, Carbone S. Time of eating and cardiorespiratory fitness in patients with heart failure with preserved ejection fraction and obesity. *Nutr Metab Cardiovasc Dis*. 2021 Jul 22;31(8):2471-2473. doi: 10.1016/j.numecd.2021.04.018. Epub 2021 Jun 7. PMID: 34112580; PMCID: PMC8277699.
49. Marawan A, Thomas GK, Canada JM, Billingsley HE, **Dixon DL**, Van Tassell BW, Kadariya D, Markley R, Rotelli B, Shah KB, Kang L, Celi FS, Abbate A, Carbone S. Edema Index Predicts Cardiorespiratory Fitness in Patients With Heart Failure With Reduced Ejection Fraction and Type 2 Diabetes Mellitus. *J Am Heart Assoc*. 2021 Apr 20;10(8):e018631. doi: 10.1161/JAHA.120.018631. Epub 2021 Apr 7. PMID: 33825487; PMCID: PMC8174175.
50. Lombardi M, Carbone S, Del Buono MG, Chiabrando JG, Vescovo GM, Camilli M, Montone RA, Vergallo R, Abbate A, Biondi-Zoccai G, **Dixon DL**, Crea F. Omega-3 fatty acids supplementation and risk of atrial fibrillation: an updated meta-analysis of randomized controlled trials. *Eur Heart J Cardiovasc Pharmacother*. 2021 Jul 23;7(4):e69-e70. doi: 10.1093/ehjcvp/pvab008. PMID: 33910233; PMCID: PMC8302253.
51. Alagheband Z, Zachariah S, Thomas D, **Dixon DL**. Lipid profile outcome gaps of Arabs and South Asians receiving chronic statin therapy. *Int J Res Pharm Sci*. 2021;11(SPL4):2194-2200. doi: 10.26452/ijrps.v11iSPL4.4442.
52. Salgado TM, Barker MR, Frerichs JD, Musselman KT, **Dixon DL**, Fernandez-Llimos F. Identifying Training Needs and Active Information Opportunities in Primary Care Through the Analysis of Drug Information Requests. *J Pharm Pract*. 2022 Aug;35(4):559-567. doi: 10.1177/0897190021996976. Epub 2021 Mar 5. PMID: 33663257.
53. Fatani N, **Dixon DL**, Van Tassell BW, Fanikos J, Buckley LF. Systolic Blood Pressure Time in Target Range and Cardiovascular Outcomes in Patients With Hypertension. *J Am Coll Cardiol*. 2021 Mar 16;77(10):1290-1299. doi: 10.1016/j.jacc.2021.01.014. PMID: 33706870; PMCID: PMC7959178.
 - **Editorial** Bakris G, Sternlicht H. Time in Therapeutic Range: Redefining "Optimal" Blood Pressure Control. *J Am Coll Cardiol*. 2021 Mar 16;77(10):1300-1301. doi: 10.1016/j.jacc.2021.01.019. PMID: 33706871.
54. Salgado TM, Reynolds TN, Frankart LM, Holdford DA, Dipiro JT; VCU School of Pharmacy KPIs Redefinition Taskforce [...**Dixon DL**]. A key performance indicators redefinition initiative at a school of pharmacy using a modified Delphi consensus technique. *Pharm Pract (Granada)*. 2020 Oct Dec;18(4):2120. doi: 10.18549/PharmPract.2020.4.2120. Epub 2020 Nov 24. PMID: 33294062; PMCID: PMC7699828.

55. *Khaddage SJ, Patterson JA, Sargent LJ, Price ET, **Dixon DL**. Sex and Age Differences in Ambulatory Blood Pressure Monitoring Tolerability. *Am J Hypertens*. 2020 Nov 12;hpaa182. doi: 10.1093/ajh/hpaa182. Epub ahead of print. PMID: 33180905.
56. Lombardi M, Chiabrando JG, Vescovo GM, Bressi E, Del Buono MG, Carbone S, Koenig RA, Van Tassell BW, Abbate A, Biondi-Zoccai G, **Dixon DL**. Impact of Different Doses of Omega-3 Fatty Acids on Cardiovascular Outcomes: a Pairwise And Network Meta-analysis. *Curr Atheroscler Rep*. 2020 Jul 16;22(9):45. doi: 10.1007/s11883-020-00865-5. PMID: 32671519.
57. **Dixon DL**, Patterson JA, Gatewood S, Kaefer T, Jadallah J, Curtis M, Hawkey L, Grigsby J, Salgado TM, Holdford DA. Development and feasibility of a community pharmacy-driven 24-hour ambulatory blood pressure monitoring service. *J Am Pharm Assoc* (2003). 2020 Nov-Dec;60(6):e332 e340. doi: 10.1016/j.japh.2020.06.007. Epub 2020 Jul 19. PMID: 32665096.
58. Carbone S, Billingsley HE, Canada JM, Bressi E, Rotelli B, Kadariya D, **Dixon DL**, Markley R, Trankle CR, Cooke R, Rao K, B Shah K, Medina de Chazal H, Chiabrando JG, Vecchié A, Dell M, L Mihalick V, Bogaev R, Hart L, Van Tassell BW, Arena R, Celi FS, Abbate A. The effects of canagliflozin compared to sitagliptin on cardiorespiratory fitness in type 2 diabetes mellitus and heart failure with reduced ejection fraction: The CANA-HF study. *Diabetes Metab Res Rev*. 2020 Nov;36(8):e3335. doi: 10.1002/dmrr.3335. Epub 2020 Jun 15. PMID: 32415802; PMCID: PMC7685099.
59. **Dixon DL**, Khaddage S, Bhagat S, Koenig RA, Salgado TM, Baker WL. Effect of pharmacist interventions on reducing low-density lipoprotein cholesterol (LDL-C) levels: A systematic review and meta-analysis. *J Clin Lipidol*. 2020 May-Jun;14(3):282-292.e4. doi: 10.1016/j.jacl.2020.04.004. Epub 2020 Apr 15. PMID: 32418821.
60. Abbate A, Trankle CR, Buckley LF, Lipinski MJ, Appleton D, Kadariya D, Canada JM, Carbone S, Roberts CS, Abouzaki N, Melchior R, Christopher S, Turlington J, Mueller G, Garnett J, Thomas C, Markley R, Wohlford GF, Puckett L, Medina Chazal H, Chiabrando JG, Bressi E, Del Buono MG, Schatz A, Vo C, **Dixon DL**, Biondi-Zoccai GG, Kontos MC, Van Tassell BW. Interleukin-1 Blockade Inhibits the Acute Inflammatory Response in Patients With ST-Segment-Elevation Myocardial Infarction. *J Am Heart Assoc*. 2020 Mar 3;9(5):e014941. doi: 10.1161/JAHA.119.014941. Epub 2020 Mar 3. PMID: 32122219; PMCID: PMC7335541.
61. Jia X, Ramsey DJ, Rifai MA, Ahmed ST, Akeroyd JM, **Dixon DL**, Gluckman TJ, Nambi V, Ballantyne CM, Petersen LA, Stone NJ, Virani SS. Impact of Lipid Monitoring on Treatment Intensification of Cholesterol Lowering Therapies (from the Veterans Affairs Healthcare System). *Am J Cardiol*. 2020 Mar 15;125(6):874-879. doi: 10.1016/j.amjcard.2019.12.030. Epub 2019 Dec 27. PMID: 31952841.
62. Lombardi M, Chiabrando JG, Vescovo GM, Bressi E, Del Buono MG, Carbone S, Koenig R, Van Tassell BW, **Dixon DL**, Abbate A, Biondi Zoccai G. Efficacy of different doses of omega-3 fatty acids on cardiovascular outcomes: rationale and design of a network meta-analysis. *Minerva Cardio Angiol*. 2020 Feb;68(1):47-50. doi: 10.23736/S0026-4725.19.05117-X. PMID: 32107906.
63. **Dixon DL**, Baker W. Short-term impact of Altmetric Attention Scores on citation counts in selected major pharmacy journals. *J Am Coll Clin Pharm*. 2020;3(1):10-14. doi: 10.1002/jac5.1141. Epub 2019 June 1.
 - **Editorial:** Thompson DF. Altmetrics: Not ready for PrimeTime? *J Am Coll Clin Pharm*. 2019;3(1):4-5. doi: 10.1002/jac5.1165.
64. **Dixon DL**, Parod ED, Sisson EM, Van Tassell BW, Nadpara P, Dow A. Impact of a pharmacist physician collaborative care model on time-in-therapeutic blood pressure range in patients with hypertension. *J Am Coll Clin Pharm*. 2020;3(2):404409. doi: 10.1002/jac5.1115. Epub 11 Apr 2019.

65. Gipson GT, Carbone S, Wang J, **Dixon DL**, Jovin IS, Carl DE, Gehr TW, Ghosh S. Impaired Delivery of Cholesterol Effluxed From Macrophages to Hepatocytes by Serum From CKD Patients May Underlie Increased Cardiovascular Disease Risk. *Kidney Int Rep*. 2019 Nov 9;5(2):199-210. doi: 10.1016/j.ekir.2019.11.003. PMID: 32043034; PMCID: PMC7000844.
66. Salgado TM, Patterson JA, Bajaj SK, Lajthia E, Zimmerman KM, Fernandez-Llimos F, **Dixon DL**. Characterization of pharmacy practice research centers across the United States. *Res Social Adm Pharm*. 2020 Feb;16(2):230-237. doi: 10.1016/j.sapharm.2019.05.009. Epub 2019 May 22. PMID: 31155477.
67. **Dixon DL**, Salgado TM, Luther JM, Byrd JB. Medicare reimbursement policy for ambulatory blood pressure monitoring: A qualitative analysis of public comments to the Centers for Medicare and Medicaid Services. *J Clin Hypertens (Greenwich)*. 2019 Dec;21(12):1803-1809. doi: 10.1111/jch.13719. Epub 2019 Oct 23. PMID: 31642596; PMCID: PMC7018518.
 - **Editorial:** Ash GI. Revisions of Medicare reimbursement policy for ambulatory blood pressure monitoring and the role of qualitative analysis. *J Clin Hypertens (Greenwich)*. 2019 Dec;21(12):1810-1812. doi: 10.1111/jch.13715. Epub 2019 Oct 23. PMID: 31642575.
68. Carbone S, Billingsley HE, Canada JM, Kadariya D, Medina de Chazal H, Rotelli B, Potere N, Paudel B, Markley R, **Dixon DL**, Trankle CR, Van Tassell BW, Celi FS, Abbate A. Unsaturated Fatty Acids to Improve Cardiorespiratory Fitness in Patients With Obesity and HFpEF: The UFA-Preserved Pilot Study. *JACC Basic Transl Sci*. 2019 Aug 26;4(4):563-565. doi: 10.1016/j.jacbts.2019.04.001. PMID: 31468011; PMCID: PMC6712039.
69. Van Tassell BW, Trankle CR, Canada JM, Carbone S, Buckley L, Kadariya D, Del Buono MG, Billingsley H, Wohlford G, Viscusi M, Oddi-Erdle C, Abouzaki NA, **Dixon D**, Biondi-Zoccai G, Arena R, Abbate A. IL-1 Blockade in Patients With Heart Failure With Preserved Ejection Fraction. *Circ Heart Fail*. 2018 Aug;11(8):e005036. doi: 10.1161/CIRCHEARTFAILURE.118.005036. PMID: 30354558.
70. Carbone S, Canada JM, Billingsley HE, Kadariya D, **Dixon DL**, Trankle CR, Buckley LF, Markley R, Vo C, Medina de Chazal H, Christopher S, Buzzetti R, Van Tassell BW, Abbate A. Effects of empagliflozin on cardiorespiratory fitness and significant interaction of loop diuretics. *Diabetes Obes Metab*. 2018 Aug;20(8):2014-2018. doi: 10.1111/dom.13309. Epub 2018 Apr 23. PMID: 29603546; PMCID: PMC6043379.
71. Buckley LF, **Dixon DL**, Wohlford GF 4th, Wijesinghe DS, Baker WL, Van Tassell BW. Effect of intensive blood pressure control in patients with type 2 diabetes mellitus over 9 years of follow-up: A subgroup analysis of high-risk ACCORDION trial participants. *Diabetes Obes Metab*. 2018 Jun;20(6):1499-1502. doi: 10.1111/dom.13248. Epub 2018 Mar 2. PMID: 29424469.
 - **Editorial:** Laffin LJ, Bakris GL. Results of ACCORDIAN in ACCORD with lower blood pressure begetting lower mortality in patients with diabetes. *Diabetes Obes Metab*. 2018 Jun;20(6):1335-1336. doi: 10.1111/dom.13249. Epub 2018 Feb 28. PMID: 29424470; PMCID: PMC5948152.
72. Bucheit JD, Helsing H, Nadpara P, Virani SS, **Dixon DL**. Clinical pharmacist understanding of the 2013 American College of Cardiology/American Heart Association cholesterol guideline. *J Clin Lipidol*. 2018 Mar-Apr;12(2):367-374.e3. doi: 10.1016/j.jacl.2017.11.010. Epub 2017 Dec 6. PMID: 29277495.
73. **Dixon DL**, Sisson EM, Parod ED, Van Tassell BW, Nadpara PA, Carl D, W Dow A. Pharmacist physician collaborative care model and time to goal blood pressure in the uninsured population. *J Clin Hypertens (Greenwich)*. 2018 Jan;20(1):88-95. doi: 10.1111/jch.13150. Epub 2017 Dec 13. PMID: 29237095.
 - **Editorial:** Carter BL. Collaborative care model for hypertension. *J Clin Hypertens (Greenwich)*. 2018 Jan;20(1):96-97. doi: 10.1111/jch.13142. Epub 2017 Dec 13. PMID: 29237101.

74. Van Tassell BW, Canada J, Carbone S, Trankle C, Buckley L, Oddi Erdle C, Abouzaki NA, **Dixon D**, Kadariya D, Christopher S, Schatz A, Regan J, Viscusi M, Del Buono M, Melchior R, Mankad P, Lu J, Sculthorpe R, Biondi-Zoccai G, Lesnefsky E, Arena R, Abbate A. Interleukin-1 Blockade in Recently Decompensated Systolic Heart Failure: Results From REDHART (Recently Decompensated Heart Failure Anakinra Response Trial). *Circ Heart Fail*. 2017 Nov;10(11):e004373. doi: 10.1161/CIRCHEARTFAILURE.117.004373. PMID: 29141858.
75. Buckley LF, **Dixon DL**, Wohlford GF 4th, Wijesinghe DS, Baker WL, Van Tassell BW. Intensive Versus Standard Blood Pressure Control in SPRINT-Eligible Participants of ACCORD-BP. *Diabetes Care*. 2017 Dec;40(12):1733-1738. doi: 10.2337/dc17-1366. Epub 2017 Sep 25. PMID: 28947569.
76. Carbone S, Canada JM, Buckley LF, Trankle CR, Billingsley HE, **Dixon DL**, Mauro AG, Dessie S, Kadariya D, Mezzaroma E, Buzzetti R, Arena R, Van Tassell BW, Toldo S, Abbate A. Dietary Fat, Sugar Consumption, and Cardiorespiratory Fitness in Patients with Heart Failure with Preserved Ejection Fraction. *JACC Basic Transl Sci*. 2017 Oct 30;2(5):513-525. doi: 10.1016/j.jacbts.2017.06.009. PMID: 30062167.
77. Baker WL, Buckley LF, Kelly MS, Bucheit JD, Parod ED, Brown R, Carbone S, Abbate A, **Dixon DL**. Effects of Sodium Glucose Cotransporter 2 Inhibitors on 24-Hour Ambulatory Blood Pressure: A Systematic Review and Meta-Analysis. *J Am Heart Assoc*. 2017 May 18;6(5):e005686. doi: 10.1161/JAHA.117.005686. PMID: 28522675.
78. Trankle C, Canada JM, Buckley L, Carbone S, **Dixon D**, Arena R, Van Tassell B, Abbate A. Impaired myocardial relaxation with exercise determines peak aerobic exercise capacity in heart failure with preserved ejection fraction. *ESC Heart Fail*. 2017 Aug;4(3):351-355. doi: 10.1002/ehf2.12147. Epub 2017 May 6. PMID: 28772034.
79. Van Tassell BW, Buckley LF, Carbone S, Trankle CR, Canada JM, **Dixon DL**, Abouzaki N, Oddi Erdle C, Biondi-Zoccai G, Arena R, Abbate A. Interleukin-1 blockade in heart failure with preserved ejection fraction: rationale and design of the Diastolic Heart Failure Anakinra Response Trial 2 (D-HART2). *Clin Cardiol*. 2017 Sep;40(9):626-632. doi: 10.1002/clc.22719. Epub 2017 May 5. PMID: 28475816; PMCID: PMC5744484.
80. Carbone S, Canada JM, Buckley LF, Trankle CR, **Dixon DL**, Buzzetti R, Arena R, Van Tassell BW, Abbate A. Obesity Contributes to Exercise Intolerance in Heart Failure With Preserved Ejection Fraction. *J Am Coll Cardiol*. 2016 Dec 6;68(22):2487-2488. doi: 10.1016/j.jacc.2016.08.072. PMID: 27908355.
81. Van Tassell BW, Abouzaki NA, Oddi Erdle C, Carbone S, Trankle CR, Melchior RD, Turlington JS, Thurber CJ, Christopher S, **Dixon DL**, Fronk DT, Thomas CS, Rose SW, Buckley LF, Dinarello CA, Biondi-Zoccai G, Abbate A. Interleukin-1 Blockade in Acute Decompensated Heart Failure: A Randomized, Double-Blinded, Placebo-Controlled Pilot Study. *J Cardiovasc Pharmacol*. 2016 Jun;67(6):544-51. doi: 10.1097/FJC.0000000000000378. PMID: 26906034.
82. Sisson EM, **Dixon DL**, Kildow DC, Van Tassell BW, Carl DE, Varghese D, Electricwala B, Carroll NV. Effectiveness of a Pharmacist-Physician Team-Based Collaboration to Improve Long-Term Blood Pressure Control at an Inner-City Safety-Net Clinic. *Pharmacotherapy*. 2016 Mar;36(3):342-7. doi: 10.1002/phar.1710. Epub 2016 Feb 24. PMID: 26917116.
83. **Dixon DL**, Dunn SP, Kelly MS, McLlarky TR, Brown RE. Effectiveness of Pharmacist-Led Amiodarone Monitoring Services on Improving Adherence to Amiodarone Monitoring Recommendations: A Systematic Review. *Pharmacotherapy*. 2016 Feb;36(2):230-6. doi: 10.1002/phar.1697. Epub 2016 Feb 5. PMID: 26846446.
84. Canada JM, Fronk DT, Cei LF, Carbone S, Erdle CO, Abouzaki NA, Melchior RD, Thomas CS, Christopher S, Turlington JS, Trankle CR, Thurber CJ, Evans RK, **Dixon DL**, Van Tassell BW, Arena R, Abbate A. Usefulness

of C-Reactive Protein Plasma Levels to Predict Exercise Intolerance in Patients with Chronic Systolic Heart Failure. *Am J Cardiol*. 2016 Jan 1;117(1):116-20. doi: 10.1016/j.amjcard.2015.10.020. Epub 2015 Oct 19. PMID: 26546248.

85. Bishop S, Stewart K, **Dixon D**, Sicat B, Wolver S. Interprofessional education team-based learning series: obesity module. *MedEdPORTAL*. 2015;11:10125. doi: 10.15766/mep_2374-8265.10125.
86. **Dixon D**, Lyles A, Sicat B, Lee B, Rybarczyk B, Lord B. Interprofessional team-based learning module: anticoagulation. *MedEdPORTAL*. 2013;9:9334. doi: 10.15766/mep_2374-8265.9334.
87. Yoder VG, **Dixon DL**, Barnette DJ, Beardsley JR. Short-term outcomes of an employer-sponsored diabetes management program at an ambulatory care pharmacy clinic. *Am J Health Syst Pharm*. 2012 Jan 1;69(1):69-73. doi: 10.2146/ajhp110041. PMID: 22180556.
88. *Gerrald KR, **Dixon DL**, Barnette DJ, Williams VG. Evaluation of a pharmacist-managed lipid clinic that uses point-of care lipid testing. *J Clin Lipidol*. 2010 Mar-Apr;4(2):120-5. doi: 10.1016/j.jacl.2010.02.001. Epub 2010 Feb 6. PMID: 21122639.
89. **Dixon D**, Peek B, Reeve R. Safety of enoxaparin bridge therapy in patients with mechanical heart valves. *Ann Pharmacother*. 2008 Jan;42(1):143-4. doi: 10.1345/aph.1K412. Epub 2007 Nov 27. PMID: 18042810.

Review Articles and Invited Publications

1. Kelly MS, Lewis J, Zuch D, Rogowsky MR, **Dixon DL**. Olezarsen and Plozasiran: Novel apoC-III targeting medications for the treatment of hypertriglyceridemia. *J Cardiovasc Pharmacol*. 2026 Jul 6. doi: 10.1097/FJC.0000000000001854. Epub ahead of print. PMID: 42407025.
2. **Dixon DL**, Jurga T, Kelly M, Landup D, Lu Y, Macaulay T, Munger M, Norgard N, Rogers KC, Trujillo T. Key Articles and Guidelines in the Management of Chronic Coronary Disease. *J Pharm Pract*. 2025 Oct 29:8971900251394069. doi: 10.1177/08971900251394069. Epub ahead of print. PMID: 41163183.
3. Alhomoud IS, Wheeler SE, **Dixon DL**. Repurposing Incretin Therapies: A Narrative Review of Emerging Indications Across Cardiometabolic, Liver, Kidney, Neurological, Psychiatric, and Other Systems. *Can J Physiol Pharmacol*. 2025 May 14. doi: 10.1139/cjpp-2025-0038. Epub ahead of print. PMID: 40367521. **[Invited Review]**
4. Garwood CL, Cabral KP, Brown R, **Dixon DL**. Current and emerging PCSK9-directed therapies to reduce LDL-C and ASCVD risk: A state-of-the-art review. *Pharmacotherapy*. 2025 Jan;45(1):54-65. doi: 10.1002/phar.4635. Epub 2024 Dec 16. PMID: 39679827; PMCID: PMC11755694. **[Invited Review]**
5. Alhomoud IS, Talasaz AH, Chandrasekaran P, Brown R, Mehta A, **Dixon DL**. Incretin hormone agonists: Current and emerging pharmacotherapy for obesity management. *Pharmacotherapy*. 2024 Sep 3. doi: 10.1002/phar.4607. Epub ahead of print. PMID: 39225417.
6. *Nguyen M, Asgharpour A, **Dixon DL**, Sanyal AJ, Mehta A. Emerging therapies for MASLD and their impact on plasma lipids. *Am J Prev Cardiol*. 2024 Feb 5;17:100638. doi: 10.1016/j.ajpc.2024.100638. PMID: 38375066; PMCID: PMC10875196.
7. *Bohmke NJ, **Dixon DL**, Kirkman DL. Chrono-nutrition for hypertension. *Diabetes Metab Res Rev*. 2024 Jan;40(1):e3760. doi: 10.1002/dmrr.3760. PMID: 38287721.

8. *Alhomoud IS, Talasaz A, Mehta A, Kelly M, Sisson EM, Bucheit JD, Brown R, **Dixon DL**. Role of Lipoprotein(a) in Atherosclerotic Cardiovascular Disease: A Review of Current and Emerging Therapies. *Pharmacotherapy*. 2023 Jul 18. doi: 10.1002/phar.2851. Epub ahead of print. PMID: 37464942. **[Invited Review]**
9. *Cutrell S, Alhomoud IS, Mehta A, Talasaz AH, Van Tassell B, **Dixon DL**. ACE-Inhibitors in Hypertension: A Historical Perspective and Current Insights. *Curr Hypertens Rep*. 2023 Jun 7. doi: 10.1007/s11906-023-01248-2. Epub ahead of print. PMID: 37284934. **[Invited Review]**
10. Mehta A, **Dixon DL (co-first author)**, Saeed A, Kelly MS, Gulati M, Shapiro MD, Sperling LS, Virani SS. With Current Safety and Efficacy Data, Should Statins Be Made Available as Nonprescription Over-the-Counter Drugs? *Curr Cardiol Rep*. 2023 May;25(5):423-430. doi: 10.1007/s11886-023-01861-2. Epub 2023 Mar 27. PMID: 36971960. **[Invited Review]**
11. Agarwala A, Satish P, Al Rifai M, Mehta A, Cainzos-Achirica M, Shah NS, Kanaya AM, Sharma GV, **Dixon DL**, Blumenthal RS, Natarajan P, Nasir K, Virani SS, Patel J. Identification and Management of Atherosclerotic Cardiovascular Disease Risk in South Asian Populations in the U.S. *JACC Adv*. 2023 Mar;2(2):100258. <https://doi.org/10.1016/j.jacadv.2023.100258>.
12. Kakavand H, Aghakouchakzadeh M, Shahi A, Virani SS, **Dixon DL**, Van Tassell BW, Talasaz AH. A stepwise approach to prescribing novel lipid-lowering medications. *J Clin Lipidol*. 2022 Nov-Dec;16(6):822-832. doi: 10.1016/j.jacl.2022.10.003. Epub 2022 Oct 19. PMID: 36522804.
13. **Dixon DL**. The impact of PCSK9 modulation on cardiovascular outcomes: recent advances and the managed care implications. *Am J Manag Care*. 2022 Sep;28(8 Suppl):S139-S147. doi: 10.37765/ajmc.2022.89269. PMID: 36493346. **[Invited Review]**
14. **Dixon DL**, Patel J, Spence R, Talasaz AH, Abbate A, Wiggins BS. Select drug-drug interactions with colchicine and cardiovascular medications: A review. *Am Heart J*. 2022 Oct;252:42-50. doi: 10.1016/j.ahj.2022.06.002. Epub 2022 Jun 14. PMID: 35714680.
15. Talasaz AH, Sadeghipour P, Aghakouchakzadeh M, Dreyfus I, Kakavand H, Ariannejad H, Gupta A, Madhavan MV, Van Tassell BW, Jimenez D, Monreal M, Vaduganathan M, Fanikos J, **Dixon DL**, Piazza G, Parikh SA, Bhatt DL, Lip GYH, Stone GW, Krumholz HM, Libby P, Goldhaber SZ, Bikdeli B. Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19: JACC State-of-the-Art Review. *J Am Coll Cardiol*. 2021 Oct 19;78(16):1635-1654. doi: 10.1016/j.jacc.2021.08.021. PMID: 34649702
16. Barry AR, **Dixon DL**. Omega-3 fatty acids for the prevention of atherosclerotic cardiovascular disease. *Pharmacotherapy*. 2021 Dec;41(12):1056-1065. doi: 10.1002/phar.2615. Epub 2021 Aug 30. PMID: 34431129.
17. Bonaventura A, Vecchié A, Dagna L, Martinod K, **Dixon DL**, Van Tassell BW, Dentali F, Montecucco F, Massberg S, Levi M, Abbate A. Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19. *Nat Rev Immunol*. 2021 May;21(5):319-329. doi: 10.1038/s41577-021-00536-9. Epub 2021 Apr 6. PMID: 33824483.
18. J Sargent L, Mackiewicz M, Roman Y, Diallo A, Russell S, Falls K, Zimmerman KM, **Dixon DL**, Prom-Wormley E, Hobgood S, Lageman SK, Zanjani F, Price ET. The Translational Approaches to Personalized Health Collaborative: Pharmacogenomics for African American Older Adults. *Clin Transl Sci*. 2021 Mar;14(2):437-444. doi: 10.1111/cts.12885. Epub 2020 Oct 7. PMID: 33026148; PMCID: PMC7993264.

19. Roman YM, **Dixon DL**, Salgado TM, Price ET, Zimmerman KM, Sargent L, Slattum PW. Challenges in pharmacotherapy for older adults: a framework for pharmacogenomics implementation. *Pharmacogenomics*. 2020 Jun;21(9):627-635. doi: 10.2217/pgs-2019-0198. Epub 2020 May 19. PMID: 32425117.
20. **Dixon DL**, Van Tassell BW, Vecchié A, Bonaventura A, Talasaz AH, Kakavand H, D'Ascenzo F, Perciaccante A, Castagno D, Ammirati E, Biondi-Zoccai G, Stevens MP, Abbate A. Cardiovascular Considerations in Treating Patients With Coronavirus Disease 2019 (COVID-19). *J Cardiovasc Pharmacol*. 2020 May;75(5):359-367. doi: 10.1097/FJC.0000000000000836. PMID: 32282502; PMCID: PMC7219860. **[Invited Rapid Communication]**
21. *Wagner TD, Jones MC, Salgado TM, **Dixon DL**. Pharmacist's role in hypertension management: a review of key randomized controlled trials. *J Hum Hypertens*. 2020 Jul;34(7):487-494. doi: 10.1038/s41371-020-0331-7. Epub 2020 Apr 1. PMID: 32238889. **[Invited Review]**
22. **Dixon DL**. Catch of the Day: Icosapent Ethyl for Reducing Cardiovascular Risk. *Am J Med*. 2020 Jul;133(7):802-804. doi: 10.1016/j.amjmed.2020.03.006. Epub 2020 Mar 31. PMID: 32243872. **[Invited Review]**
23. *Board C, Kelly MS, Shapiro MD, **Dixon DL**. PCSK9 Inhibitors in Secondary Prevention-An Opportunity for Personalized Therapy. *J Cardiovasc Pharmacol*. 2020 May;75(5):410-420. doi: 10.1097/FJC.0000000000000809. PMID: 32379108. **[Invited Review]**
24. Wiggins BS, **Dixon DL**, Neyens RR, Page RL 2nd, Gluckman TJ. Select Drug-Drug Interactions With Direct Oral Anticoagulants: JACC Review Topic of the Week. *J Am Coll Cardiol*. 2020 Mar 24;75(11):1341-1350. doi: 10.1016/j.jacc.2019.12.068. PMID: 32192661.
25. Bucheit JD, Pamulapati LG, Carter N, Malloy K, **Dixon DL**, Sisson EM. Oral Semaglutide: A Review of the First Oral Glucagon-Like Peptide 1 Receptor Agonist. *Diabetes Technol Ther*. 2020 Jan;22(1):10-18. doi: 10.1089/dia.2019.0185. Epub 2019 Oct 1. PMID: 31436480.
26. Wiggins BS, **Dixon D**, Bellone J, Gasbarro N, Marrs JC, Tran R. Key Articles and Guidelines in the Management of Dyslipidemia: 2019 Update. *J Pharm Pract*. 2020 Dec;33(6):882-894. doi: 10.1177/0897190019868413. Epub 2019 Aug 11. PMID: 31401932.
27. **Dixon DL**, Sharma G, Sandesara PB, Yang E, Braun LT, Mensah GA, Sperling LS, Deedwania PC, Virani SS. Therapeutic Inertia in Cardiovascular Disease Prevention: Time to Move the Bar. *J Am Coll Cardiol*. 2019 Oct 1;74(13):1728-1731. doi: 10.1016/j.jacc.2019.08.014. PMID: 31558257. **[Invited Review]**
28. Carbone S, **Dixon DL**. The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus. *Cardiovasc Diabetol*. 2019 May 28;18(1):64. doi: 10.1186/s12933-019-0869-2. PMID: 31138195
29. **Dixon DL**, Pamulapati LG, Bucheit JD, Sisson EM, Smith SR, Kim CJ, Wohlford GF, Pozen J. Recent Updates on the Use of PCSK9 Inhibitors in Patients with Atherosclerotic Cardiovascular Disease. *Curr Atheroscler Rep*. 2019 Mar 16;21(5):16. doi: 10.1007/s11883-019-0778-6. PMID: 30877491. **[Invited Review]**
30. Bonaventura A, Carbone S, **Dixon DL**, Abbate A, Montecucco F. Pharmacologic strategies to reduce cardiovascular disease in type 2 diabetes mellitus: focus on SGLT-2 inhibitors and GLP-1 receptor agonists. *J Intern Med*. 2019 Jul;286(1):16-31. doi: 10.1111/joim.12890. Epub 2019 Mar 19. PMID: 30888088.
31. Trivedi M, Jee J, Silva S, Blomgren C, Pontinha VM, Dixon DL, Van Tassell B, Bortner MJ, Williams C, Gilmer E, Haring AP, Halper J, Johnson BN, Kong Z, Halquis MS, Rocheleau PF, Long TE, Roper T, Wijesinghe DS.

Additive manufacturing of pharmaceuticals for precision medicine applications: A review of the promises and perils in implementation. *Additive Manufacturing*. 2018;23:319-328. doi: 10.1016/j.addma.2018.07.004. Epub 2018 Jul 18.

32. Carbone S, **Dixon DL**, Buckley LF, Abbate A. Glucose-Lowering Therapies for Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: State-of-the-Art Review. *Mayo Clin Proc*. 2018 Nov;93(11):1629-1647. doi: 10.1016/j.mayocp.2018.07.018. Erratum in: *Mayo Clin Proc*. 2019 Mar;94(3):554. PMID: 30392544.
33. *Ayers J, *Cook J, Koenig RA, Sisson EM, **Dixon DL**. Recent Developments in the Role of Coenzyme Q10 for Coronary Heart Disease: a Systematic Review. *Curr Atheroscler Rep*. 2018 May 16;20(6):29. doi: 10.1007/s11883-018-0730-1. PMID: 29766349. **[Invited Review]**
34. Littauer SL, **Dixon DL**, Mishra VK, Sisson EM, Salgado TM. Pharmacists providing care in the outpatient setting through telemedicine models: a narrative review. *Pharm Pract (Granada)*. 2017 Oct Dec;15(4):1134. doi: 10.18549/PharmPract.2017.04.1134. Epub 2017 Dec 19. PMID: 29317927.
35. Hylton Gravatt LA, Flurie RW, Lajthia E, **Dixon DL**. Clinical Guidance for Managing Statin and Antimicrobial Drug-Drug Interactions. *Curr Atheroscler Rep*. 2017 Oct 9;19(11):46. doi: 10.1007/s11883-017-0682-x. PMID: 28990114. **[Invited Review]**
36. *Kelly MS, Beavers C, Bucheit JD, Sisson EM, **Dixon DL**. Pharmacologic approaches for the management of patients with moderately elevated triglycerides (150-499 mg/dL). *J Clin Lipidol*. 2017 Jul-Aug;11(4):872-879. Doi: 10.1016/j.jacl.2017.05.014. Epub 2017 Jun 6. PMID: 28669686.
37. **Dixon DL**, Buckley LF, Trankle CR, Kadariya D, Abbate A. Clinical utility of evolocumab in the management of hyperlipidemia: patient selection and follow-up. *Drug Des Devel Ther*. 2017 Jul 11;11:2121-2129. doi: 10.2147/DDDT.S114091. PMID: 28744103; PMCID: PMC5513834. **[Invited Review]**
38. **Dixon DL**, Trankle C, Buckley L, Parod E, Carbone S, Van Tassell BW, Abbate A. A review of PCSK9 inhibition and its effects beyond LDL receptors. *J Clin Lipidol*. 2016 Sep-Oct;10(5):1073-80. doi: 10.1016/j.jacl.2016.07.004. Epub 2016 Jul 20. PMID: 27678423.
39. Buckely L, Wijesinghe D, **Dixon D**, Trankle C, Carbone S, Canada J, Van Tassell B. The State of Women's Health in 2016 and Future Perspectives. *Ann Public Health Res*. 2016;3(2):1041.
40. Ogbonna KC, **Dixon DL**. Critical appraisal of dabigatran in the treatment of deep vein thrombosis and pulmonary embolism. *J Blood Med*. 2015 Jun 11;6:177-84. doi: 10.2147/JBM.S54033. PMID: 26185477.
41. Abbate A, Van Tassell BW, Canada JM, **Dixon DL**, Arena RA, Biondi-Zoccai G. Pharmacologic and surgical interventions to improve functional capacity in heart failure. *Heart Fail Clin*. 2015 Jan;11(1):117-24. doi: 10.1016/j.hfc.2014.08.005. Epub 2014 Oct 3. PMID: 25432480.
42. Carbone S, Buckley L, Trankle C, Canada J, **Dixon D**, Van Tassell B, Buzzetti R, Abbate A. Obesity and Heart Failure: Can Nutrition Status Explain the Paradoxical Relationship? *EC Cardiology*. 2015;2(2):94-98.
43. **Dixon DL**, Donohoe KL, Ogbonna KC, Barden SM. Current drug treatment of hyperlipidemia in older adults. *Drugs Aging*. 2015 Feb;32(2):127-38. doi: 10.1007/s40266-015-0240-6. PMID: 25637391. **[Invited Review]**
44. *Crist LW, **Dixon DL**. Considerations for dofetilide use in the elderly. *Consult Pharm*. 2014 Apr;29(4):270-4. doi: 10.4140/TCP.n.2014.270. PMID: 24704896.

45. **Dixon DL**, Sisson EM, Butler M, Higbea A, Muoio B, Turner B. Lomitapide and mipomersen: novel lipid-lowering agents for the management of familial hypercholesterolemia. *J Cardiovasc Nurs*. 2014 Sep-Oct;29(5):E7-E12. doi: 10.1097/JCN.0000000000000104. PMID: 24231894.

Editorials, Commentaries, Case Reports

1. Saseen JJ, **Dixon DL**. Nonstatins for LDL-C lowering: An expansion whose time has come. *J Clin Lipidol*. 2026 Apr 20:S1933-2874(26)00117-0. doi: 10.1016/j.jacl.2026.04.017. Epub ahead of print. PMID: 42106255. **[Invited Commentary]**
2. O'Connell B, Sahay A, Verma A, Bosworth HB, Jurga T, Vardeny O, Hess PL, **Dixon DL**, Van Tassell BW, Heidenreich PA, Sandhu AT. Call to Action: Transformative Role of Pharmacists to Augment Guideline-Directed Medical Therapy Optimization. *JACC Heart Fail*. 2025 Jul 10;13(9):102552. doi: 10.1016/j.jchf.2025.102552. Epub ahead of print. PMID: 40644946.
3. Watson KE, Tsuyuki RT, **Dixon DL**, Liu S, Al Hamarneh YN. Accessibility reality check. *Can Pharm J (Ott)*. 2024 Jun 10;157(4):155-160. doi: 10.1177/17151635241256621. PMID: 39092088; PMCID: PMC11290581.
4. **Dixon DL**, Carbone S. Is Metformin Cardioprotective? A New Piece to the Puzzle. *J Cardiovasc Pharmacol*. 2024 Aug 1;84(2):155-157. doi: 10.1097/FJC.0000000000001601. PMID: 39115717. **[Invited Editorial]**
5. **Dixon DL**, Mehta A, Moneta G. Team-Based Care to Overcome Therapeutic Inertia in PAD: A Step in the Right Direction. *J Am Coll Cardiol*. 2024 Jun 25;83(25):2671-2673. doi: 10.1016/j.jacc.2024.04.033. PMID: 38897677. **[Invited Editorial]**
6. **Dixon DL**. Is the "Clinical Pharmacist" Designation Still Relevant? *J Am Coll Clin Pharm*. 2023;6:672-674. doi: 10.1002/jac5.1835
7. Moroni F, Ayers MP, **Dixon DL**, Abbate A. Proprotein Convertase Subtilisin Kexin-9 Inhibitors (PCSK9i) in Atherosclerotic Cardiovascular Disease: Real-World Data Welcome. *J Cardiovasc Pharmacol*. 2023 May 1;81(5):336-338. doi: 10.1097/FJC.0000000000001411. PMID: 37043382. **[Invited Editorial]**
8. Kelly M, **Dixon DL**. Inclisiran: A knight in shining armor? *Am Heart J Plus*. 2022 Apr 29;16:100138. doi: 10.1016/j.ahjo.2022.100138. PMID: 38559283; PMCID: PMC10976279.
9. **Dixon DL**, Sisson EM, Pamulapati LG, Spence R, Salgado TM. An ounce of prevention is worth a pound of cure: considerations for pharmacists delivering the National Diabetes Prevention Program. *Pharm Pract (Granada)*. 2021 Apr Jun;19(2):2426. doi: 10.18549/PharmPract.2021.2.2426. Epub 2021 May 13. PMID: 34221206; PMCID: PMC8221748.
10. **Dixon DL**, Saseen JJ. Pharmacist-administered long-acting injectable PCSK9 service: A solution to improve patient access and adherence. *J Am Pharm Assoc* (2003). 2021 May-Jun;61(3):e83-e85. doi: 10.1016/j.japh.2020.12.009. Epub 2020 Dec 29. PMID: 33384242.
11. **Dixon DL**. The student loan debt crisis is undermining our profession. *J Am Pharm Assoc* (2003). 2021 Mar Apr;61(2):127-128. doi: 10.1016/j.japh.2020.11.016. Epub 2020 Dec 16. PMID: 33736840. **[Guest Editorial]**
12. **Dixon DL**. Introducing Emerging Concepts in Pharmacotherapeutics. *J Cardiovasc Pharmacol*. 2020 Oct;76(4):372-373. doi: 10.1097/FJC.0000000000000904. PMID: 33027193. **[Invited Editorial]**

13. Salgado TM, Rosenthal MM, Coe AB, Kaefer TN, **Dixon DL**, Farris KB. Primary healthcare policy and vision for community pharmacy and pharmacists in the United States. *Pharm Pract (Granada)*. 2020 Jul-Sep;18(3):2160. doi: 10.18549/PharmPract.2020.3.2160. Epub 2020 Sep 18. PMID: 33029264; PMCID: PMC7523559.
14. **Dixon DL**, Carbone S. Screening, identification, and management of prediabetes to reduce cardiovascular risk: A missed opportunity? *Diabetes Metab Res Rev*. 2020 Sep;36(6):e3316. doi: 10.1002/dmrr.3316. Epub 2020 Apr 15. PMID: 32223033.
15. **Dixon DL**, Baker WL. Measuring research impact in the 21st century: are alternative metrics the answer? *Minerva Cardio Angiol*. 2020 Aug;68(4):279-281. doi: 10.23736/S0026-4725.20.05241-X. Epub 2020 Mar 11. PMID: 32163245. **[Invited Editorial]**
16. *Billingsley HE, **Dixon DL**, Gipson G, Abbate A, Carbone S. Time restricted feeding: old tools, new packaging? *Minerva Cardio Angiol*. 2020 Dec;68(6):539-541. doi: 10.23736/S0026-4725.20.052536. Epub 2020 Mar 27. PMID: 32221275. **[Invited Editorial]**
17. Del Buono MG, Bonaventura A, Vecchié A, Wohlford GF, **Dixon DL**, Van Tassel BW, Abbate A. Sacubitril-Valsartan for the Treatment of Heart Failure: Time for a Paragon? *J Cardiovasc Pharmacol*. 2020 Feb;75(2):105-107. doi: 10.1097/FJC.0000000000000782. PMID: 31815825. **[Invited Editorial]**
18. **Dixon DL**, Wohlford GF 4th, Abbate A. Inflammation and Hypertension: Causal or Not? *Hypertension*. 2020 Feb;75(2):297-298. doi: 10.1161/HYPERTENSIONAHA.119.14195. Epub 2019 Dec 30. PMID: 31884858. **[Invited Editorial]**
19. Lajthia E, Bucheit JD, Nadpara PA, **Dixon DL**, Caldas LM, Murchie M, Sisson EM. Combination therapy with once-weekly glucagon like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a case series. *Pharm Pract (Granada)*. 2019 Oct-Dec;17(4):1588. doi: 10.18549/PharmPract.2019.4.1588. Epub 2019 Dec 12. PMID: 31897252; PMCID: PMC6935552.
20. **Dixon DL**, Virani SS. Mortality reduction with PCSK9 inhibition: A case of cautious optimism. *J Clin Lipidol*. 2019 Sep Oct;13(5):712-713. doi: 10.1016/j.jacl.2019.06.012. Epub 2019 Jul 4. PMID: 31371269. **[Invited Editorial]**
21. **Dixon DL**, Reed B. To Tweet or Not to Tweet? A Primer on Social Media for Pharmacists. *J Am Coll Clin Pharm*. 2019;2:554-562. doi: 10.1002/jac5.1120. Epub 2 May 2019. **[Invited Commentary]**
 - **Editorial:** Abebe E, Zillich AJ. Please like, follow, subscribe, and share. *J Am Coll Clin Pharm*. 2019;2:452-454.
22. Salgado TM, **Dixon DL**. Practice Forum: A new section led by the Center for Pharmacy Practice Innovation at Virginia Commonwealth University School of Pharmacy. *Pharm Pract (Granada)*. 2019 Jan-Mar;17(1):1495. doi: 10.18549/PharmPract.2019.1.1495. Epub 2019 Mar 18. PMID: 31015882; PMCID: PMC6463415.
23. **Dixon DL**, Johnson SG. Provider Status: What does it mean? *J Am Coll Clin Pharm*. 2019; 2(1):87 doi: 10.1002/jac5.1054. Epub 31 Oct 2018. **[Letter to the Editor]**
24. Noel ZR, Beavers CJ, Dunn SP, Schullo-Feulner AM, Caldas L, **Dixon DL**. Identifying Core Content for Electrocardiogram Instruction in Doctor of Pharmacy Curricula. *Am J Pharm Educ*. 2018 Dec;82(10):7009. doi: 10.5688/ajpe7009. PMID: 30643314.

25. Longyshore DS, **Dixon DL**, Noel ZR. A Modified Approach to Setting Curriculum Boundaries in Pharmacy School. *Am J Pharm Educ*. 2018 Nov;82(9):7010. doi: 10.5688/ajpe7010. PMID: 30559503.
26. Carbone S, **Dixon DL**. Selecting appropriate weight loss pharmacotherapies in older adults to reduce cardiovascular risk. *Expert Opin Pharmacother*. 2018 Sep;19(13):1399-1402. doi: 10.1080/14656566.2018.1511704. Epub 2018 Aug 16. PMID: 30113233. **[Invited Editorial]**
27. Sisson EM, **Dixon DL**, Dow AW. A Trial of Blood-Pressure Reduction in Black Barbershops. *N Engl J Med*. 2018 Jul 12;379(2):200. doi: 10.1056/NEJMc1806026. PMID: 29998726. **[Letter to the Editor]**
28. Buckley LF, **Dixon DL**, Wohlford GF 4th, Wijesinghe DS, Baker WL, Van Tassell BW. **Response to Comment** on Buckley et al. Intensive Versus Standard Blood Pressure Control in SPRINT-Eligible Participants of ACCORD-BP. *Diabetes Care* 2017;40:1733-1738. *Diabetes Care*. 2018 Jun;41(6):e86-e87. doi: 10.2337/dci17-0066. PMID: 29784701.
29. **Dixon DL**, Salgado TM, Caldas LM, Van Tassell BW, Sisson EM. The 2017 American College of Cardiology/American Heart Association hypertension guideline and opportunities for community pharmacists. *J Am Pharm Assoc (2003)*. 2018 Jul Aug;58(4):382-386. doi: 10.1016/j.japh.2018.04.027. Epub 2018 May 24. PMID: 29804824.
30. Zimmerman KM, Salgado TM, Goode JR, Sisson EM, **Dixon DL**. A Prescription for Prescribing: Ensuring Continued Pharmacist Preparedness. *Ann Pharmacother*. 2018 Jul;52(7):697-699. doi: 10.1177/1060028018763519. Epub 2018 Mar 7. PMID: 29514464. **[Invited Commentary]**
31. Sisson EM, Pamulapati L, Bucheit JD, Kelly MS, **Dixon DL**. Evolving Role of Non-Statins Therapy for the Management of Dyslipidemia and Cardiovascular Risk Reduction: Past, Present, and Future. *Pharmacotherapy*. 2018 Feb;38(2):164-171. doi: 10.1002/phar.2074. Epub 2018 Jan 10. PMID: 29266309. **[Invited Commentary]**
32. Carbone S, **Dixon DL**, Abbate A. Treatment of Hypertension to Prevent and Treat Heart Failure in Diabetic Patients Should Include Sodium Glucose Co-Transporter 2 Inhibitors. *JACC Heart Fail*. 2018 Jan;6(1):85. doi: 10.1016/j.jchf.2017.07.008. PMID: 29284585. **[Letter to the Editor]**
33. Zimmerman KM, Salgado TM, **Dixon DL**. Medication Reconciliation vs Medication Review. *JAMA*. 2017 Sep 12;318(10):965-966. doi: 10.1001/jama.2017.10552. PMID: 28898372. **[Letter to the Editor]**
34. **Dixon DL**, Salgado TM, Abbate A. Pharmacists as Integral Members of the Cardiovascular Team. *JAMA Cardiol*. 2017 Nov 1;2(11):1279-1280. doi: 10.1001/jamacardio.2017.2795. PMID: 28832861. **[Letter to the Editor]**
35. **Dixon DL**, Carbone S, Abbate A. Letter by Dixon et al Regarding Article, "Watching Television and Risk of Mortality From Pulmonary Embolism Among Japanese Men and Women: The JACC Study (Japan Collaborative Cohort)". *Circulation*. 2016 Nov 22;134(21):e499-e500. doi: 10.1161/CIRCULATIONAHA.116.024740. PMID: 27881514. **[Letter to the Editor]**
36. **Dixon DL**, Abbate A. Potassium levels in acute myocardial infarction: definitely worth paying attention to. *Eur Heart J Cardiovasc Pharmacother*. 2015 Oct;1(4):252-3. doi: 10.1093/ehjcvp/pvv029. Epub 2015 Jun 18. PMID: 27532448. **[Invited Editorial]**
37. **Dixon DL**, Williams VG. Interaction between gemfibrozil and warfarin: case report and review of the literature. *Pharmacotherapy*. 2009 Jun;29(6):744-8. doi: 10.1592/phco.29.6.744. PMID: 19476425.

Peer-Reviewed Conference Proceedings

1. Smith MA, Giara K, Bucheit JD, Goode JK, **Dixon DL**, Sisson EM, Salgado TM. The 2025 Invitational Summit on Medicaid Payment for Pharmacist Patient Care Services: Meeting proceedings. *J Am Pharm Assoc (2003)*. 2026 Feb 13;103049. doi: 10.1016/j.japh.2026.103049. Epub ahead of print. PMID: 41692175.

PEER-REVIEWED BOOK CHAPTERS (n = 13)

1. **Dixon DL**, Riche DM, Kelly MS (2026). Dyslipidemia (Chapter 35). In: Haines ST, Nolin TD, Ellingrod VL, Pose M, Cocohoba J, Holle L. eds. *DiPiro's Pharmacotherapy: A Pathophysiologic Approach*, 13e. New York, NY: McGraw Hill.
2. **Dixon DL**, Riche DM, Kelly MS (2023). Dyslipidemia (Chapter 32). In: DiPiro JT, Yee GC, Haines ST, Nolin TD, Ellingrod VL, Posey LM. eds. *DiPiro's Pharmacotherapy: A Pathophysiologic Approach*, 12e. New York, NY: McGraw Hill.
3. **Dixon DL**, Riche DM (2020). Dyslipidemia (Chapter 31). In: DiPiro JT, Yee GC, Posey L, Haines ST, Nolin TD, Ellingrod V. eds. *Pharmacotherapy: A Pathophysiologic Approach*, 11e. New York, NY: McGraw-Hill.
4. Bucheit J, **Dixon DL** (2020). *Pharmacotherapy: Dyslipidemia and Hypertension in Persons with Diabetes* (Chapter 20). In: Cornell S, ed. *The Art and Science of Diabetes Self-Management Education, Desk Reference*, 5th edition. Chicago: Association of Diabetes Care & Education Specialists.
5. **Dixon DL**. (2018). Dyslipidemia. In: Baker WL, Beavers C, Bolesta S, et al., eds. *Updates in Therapeutics®: Cardiology Pharmacy Preparatory Review Course*. Lenexa: American College of Clinical Pharmacy.
6. **Dixon DL**, Sisson EM (2018). Primary Prevention of Cardiovascular Disease (Cardiologic Care 1). In: Dong BJ, Elliot DP, eds. *Ambulatory Care Self-Assessment Program Book 1: Cardiologic Care*. Lenexa: American College of Clinical Pharmacy.
7. **Dixon DL** (2017). Best Practice for Switching Stable Warfarin Patients (Chapter 15). In: Kiser K, ed. *Oral Anticoagulation Therapy: Cases and Clinical Correlation*. Cham: Springer International Publishing. DOI 10.1007/978-3-319-54643-8_1
8. **Dixon DL** (2017). Significance of P-glycoprotein (P-gp) Drug-Drug Interactions (Chapter 29). In: Kiser K, ed. *Oral Anticoagulation Therapy: Cases and Clinical Correlation*. Cham: Springer International Publishing. DOI 10.1007/978-3-31954643-8_1
9. **Dixon DL**, Bucheit J (2017). *Pharmacotherapy: Dyslipidemia and Hypertension* (Chapter 19). In: Cornell S, ed. *The Art and Science of Diabetes Self-Management Education, Desk Reference*, 4th edition. Chicago: Association of Diabetes Care & Education Specialists.
10. **Dixon DL**, Parod E (2013). New FDA recommendations for the use of metformin in patients with mild to moderate renal impairment. Textbook Update. Access Pharmacy Website. <http://www.AccessPharmacy.com>. New York: McGraw-Hill.
11. **Dixon DL** (2015). Taking Medications (Module 4). In: Miller D, ed. *Diabetes Education Curriculum: A Guide to Successful Self-Management*, 2nd edition. Chicago: Association of Diabetes Care & Education Specialists.

12. **Dixon DL**, Sisson EM (2014). Pharmacotherapy: Dyslipidemia and Hypertension (Chapter 18). In: Mensing C, ed. The Art and Science of Diabetes Self-Management Education, Desk Reference, 3rd edition. Chicago: Association of Diabetes Care & Education Specialists.
13. Sisson EM, **Dixon DL** (2014). Pharmacotherapy for Glucose Management (Chapter 17). In: Mensing C, ed. The Art and Science of Diabetes Self-Management Education, Desk Reference, 3rd edition. Chicago: Association of Diabetes Care & Education Specialists.

PEER-REVIEWED ABSTRACTS AND POSTER PRESENTATIONS (*mentee)

International (n = 5)

1. *Wagner TD, Barker MR, Ngo PQ, Ko EE, Martin BA, Squadrito MM, Frerichs JD, Musselman KT, Shin Y, **Dixon DL**, Jones RM, Salgado TM. Contribution of clinical pharmacy services to the achievement of diabetes- and hypertension-related quality measures among Medicare patients. International Society of Pharmacoeconomics and Outcomes Research Annual International Conference. Vienna, Austria; 2022. *Value Health*. 2022;25(Suppl I,SI 12):S289.
2. *Wagner TD, **Dixon DL**, Salgado TM. The comparison of SGLT2 inhibitors and DPP-4 inhibitors on health care expenditure and utilization in patients with type 2 diabetes mellitus. International Society of Pharmacoeconomics and Outcomes Research Annual International Conference. Orlando, Florida; 2020. *Value Health* 2020;23(Suppl I,SI 17):PDB48.
3. Derington CG, King JB, Herrick JS, **Dixon DL**, Cohen JB, Shimbo D, Kronish IM, Saseen JJ, Munter P, Moran AE, Bress AP. Factors associated with antihypertensive monotherapy among US adults with treated and uncontrolled blood pressure, NHANES 2013-2018. Joint Meeting of the European Society of Hypertension (ESH) and the International Society of Hypertension (ISH) (virtual); Glasgow, UK; April 2021. *J Hyperten*. April 2021;39:e241 doi: 10.1097/01.hjh.0000747184.27176.5a.
4. Van Tassell B, Trankle CR, Kadariya D, Canada JM, Carbone S, Buckley LF, Wohlford GF, **Dixon DL**, Christopher S, Vo C, Mankad P, Dell M, Shah K, Kontos MC, Abbate A. Predictive role of C reactive protein levels in patients with ST-segment elevation acute myocardial infarction for heart failure related events. European Society of Cardiology Congress; Paris, France; September 3, 2019. *Eur J Heart Fail*. 2019;40(Suppl. S1):ehz746.0097.
5. Van Tassell B, Canada J, Carbone S, Trankle C, Buckley LF, Oddi Erdle C, Abouzaki N, **Dixon DL**, Kadariya D, Christopher S, Billingsley H, Regan J, Bhatnagar A, Lesnefsky E, Abbate A. Interleukin-1 blockade in recently decompensated systolic heart failure: the recently decompensated heart failure anakinra response trial (REDHART). 4th World Congress on Acute Heart Failure; Paris, France; May 2017. *Eur J Heart Fail*. 2017;19(Suppl. S1):368. Encore presentation: American College of Clinical Pharmacy Annual Meeting; Orlando, FL; October 2017.

National (n = 67)

1. Alebna PL, Ambrosio M, Martin M, Martey S, Van Tassell BW, **Dixon DL**, Hundley WG, Salloum F, Mehta A. Association of Lipoprotein(a) with Cardiovascular Events Among Individuals with Autoimmune Conditions. American College of Cardiology Scientific Sessions; March 30, 2025. *JACC*. 2025 Apr, 85 (12_Supplement) 385.
2. **Dixon DL**, Robinson A, Salgado TM, Carbone S, Wagner T, Hyder H, Kirschner B, Musselman K, Buffington T, Sabo R. Comparison of Prescribing Rates for SGLT2 Inhibitors and GLP1 Receptor Agonists Among Primary

Care Clinics with and Without Embedded Pharmacists. American College of Clinical Pharmacy Virtual Poster Symposium; May 22, 2024.

3. Alebna PL, Yasin A, Harley K, Ambrosio M, **Dixon DL**, Siddiqui M, Salloum FN, Mehta A. Association Between Cardiovascular Health and Metabolic Dysfunction Associated Steatosis Liver Disease (MASLD). American College of Cardiology Scientific Sessions; April 8, 2024. *J Am Coll Cardiol*. 2024 Apr, 83 (13_Supplement) 2029.
4. *Sproule TW, Mackiewicz M, Thacker L, Price E, Sargent L, **Dixon DL**. Association Between Blood Pressure and Cognitive Impairment in a Predominantly Black, Community-Dwelling, Older Adult Population. American College of Cardiology Scientific Sessions; April 8, 2024. *J Am Coll Cardiol*. 2024 Apr, 83 (13_Supplement) 1769.
5. *Tran C, *Alhomoud I, Taylor K, Kaefer T, Sabo R, **Dixon DL**. A Comparison of Community Pharmacy Measured Blood Pressure to 24-hour Ambulatory Blood Pressure Monitoring: Preliminary Findings. American College of Clinical Pharmacy Annual Meeting; November 2023.
6. **Dixon DL**, Robinson A, Salgado T, Carbone S, Wagner T, Hyder H, Kirschner B, Musselman K, Sabo R. Prescribing Patterns of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Agonists in Patients With Type 2 Diabetes at Cardiology, Endocrinology and Primary Care Visits in a Community Health System. American Heart Association Scientific Sessions; November 2023. *Circulation*. 2023;148:A12427
7. Lee T, Grandhi GR, Alebna P, Asgharpour A, **Dixon DL**, Salloum FN, Sanyal AJ, Siddiqui M, Mehta A. Discordant Association of Nonalcoholic Fatty Liver Disease With Lipoprotein(a) and Markers of Atherogenic Dyslipidemia. American Heart Association Scientific Sessions; November 2023. *Circulation*. 2023;148:A12321
8. Alebna PL, Grandhi G, Shetty N, Minhas AMK, Chew N, **Dixon DL**, Blaha MJ, Arora P, Siddiqui M, Sanyal A, Mehta A. Association of Cardiovascular Health With Nonalcoholic Fatty Liver Disease in American Adults. American Heart Association Scientific Sessions; November 2023. *Circulation*. 2023;148:A15983
9. Salgado TM, Bradford NM, Zimmerman KM, Musselman KT, Buffington TM, Hyder HS, Seaton TL, **Dixon DL**, Jones RM. Application of the consolidation framework for implementation research to explore factors affecting uptake of SGLT-2 inhibitors and GLP-1 receptor agonists in clinical practice. 15th Annual Conference on the Science of Dissemination and Implementation; December 2022.
10. *Zbyrak V, Salgado TM, **Dixon DL**, Radwan R, Sisson EM, Pamulapati LG. Factors affecting job satisfaction among board-certified pharmacists in Virginia. American College of Clinical Pharmacy Global Conference in Clinical Pharmacy; October 2022.
11. Salgado TM, Campbell C, Karim-Nejad L, Sisson EM, **Dixon DL**. Implementation of a diabetes prevention program: Participant feedback on ways to increase recruitment and adaptations to improve retention. 14th Annual Conference on the Science of Dissemination and Implementation in Health (virtual); December 2021.
12. *Jay JS, Ijioma SC, Holdford DA, **Dixon DL**, Sisson EM, Patterson JA. The Cost-Benefit of Pharmacist-Physician Collaborative Care Model vs. Usual Care on Time-in-Therapeutic Blood Pressure Range in Patients with Hypertension: From the Payer Perspective. Academy of Managed Care Pharmacy Nexus; October 2021. **Awarded Best Resident/Fellow Poster**
13. *Buckley L, Baker WL, Van Tassel BW, Cohen J, Alkhezi O, Bress AP, **Dixon DL**. Association Of Systolic Blood Pressure Time-in-target Range With Adverse Kidney And Cardiovascular Outcomes In Adults With And Without Diabetes. American Heart Association Hypertension Scientific Sessions; September 2021. *Hypertension*.

2021;78:A20. **Selected for Early Career Stage Award for Patient-Oriented or Clinical Research in Hypertension**

14. Billingsley HE, **Dixon DL**, Canada JM, Rotelli B, Kadariya D, Markley R, Van Tassell B, Celi FS, Abbate A, Carbone S. Time of Eating and Cardiorespiratory Fitness in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. American Society of Nutrition Annual Meeting (virtual); June 2021. **Abstract of Distinction**
15. *Spence R, Sisson EM, **Dixon DL**. Survey of CDC-recognized community pharmacies providing the National Diabetes Prevention Program. American College of Clinical Pharmacy Virtual Poster Symposium; May 2021.
16. **Dixon DL**, Baker W, Buckley L, Salgado TM, Van Tassell B, Carter B. Cluster randomized Trial of a Physician/Pharmacist Collaborative Model to Improve Blood Pressure Control: Post-Hoc Analysis of Time in Therapeutic Range for Systolic Blood Pressure. American College of Cardiology Scientific Sessions (virtual); May 2021. *J Am Coll Cardiol*. 2021 May, 77 (18_Supplement_1) 1477. **Selected for Oral Moderated Poster Session**
17. Radwan RM, **Dixon DL**, Salgado TM. Predictors of Obtaining Cholesterol Screening in the United States: Data from the 2014 Medical Expenditure Panel Survey. American Pharmacists Association Annual Meeting (virtual); March 2021.
18. Wagner TD, Barker MR, Squadrito MM, Frerichs JD, Martin BA, Musselman KT, Shin Y, **Dixon DL**, Jones RM, Salgado TM. Impact of clinical pharmacy services on the achievement of vaccine-related quality measures in primary care. American Pharmacists Association Annual Meeting (virtual); March 2021.
19. Billingsley HE, **Dixon DL**, Canada JM, Rotelli B, Dell M, Vecchie A, Kadariya D, Markley R, Trankle CR, Medina de Chazal H, Chiabrando JG, Dickson V, Bressi E, Van Tassell BW, Abbate A, Carbone S. Higher Skeletal Muscle Mass Index is Associated with Better Reported Quality of Life and Lower Fatigue in Patients with Heart Failure with Reduced Ejection Fraction and Type 2 Diabetes Mellitus. ASPEN Nutrition Science & Practice Conference (virtual). March 2021.
20. Billingsley HE, **Dixon DL**, Canada JM, Rotelli B, Dell M, Vecchie A, Kadariya D, Markley R, Trankle CR, Medina De Chazal H, Chiabrando GJ, Dickson V, Bressi E, Van Tassell BW, Abbate A, Carbone S. Skeletal Muscle Mass Index by Bioelectrical Impedance Analysis is Strongly Associated with Dual Energy X-Ray Absorptiometry in Patients with Heart Failure with Reduced Ejection Fraction and Type 2 Diabetes Mellitus. ASPEN Nutrition Science & Practice Conference (virtual). March 2021. **Selected for Oral Presentation**
21. **Dixon DL**, Billingsley HE, Canada JM, Trankle CR, Cooke R, Hart L, Van Tassell B, Abbate A, Carbone S. Effect of Canagliflozin compared to Sitagliptin on Serum Lipids in Patients with Type 2 Diabetes Mellitus and Heart Failure with Reduced Ejection Fraction: A Post-Hoc Analysis of the CANA-HF Study. National Lipid Association Scientific Sessions (virtual). December 10, 2020.
22. Radwan RM, Patterson JA, **Dixon DL**, Salgado TM. Predictors Of Pharmacists' Job Satisfaction: Analysis Of The 2018 Virginia Pharmacist Workforce Survey. American College of Clinical Pharmacy Annual Meeting (virtual). October 2020.
23. Wagner T, Barker MR, Squadrito MM, Frerichs JD, Martin BA, Musselman KT, Shin Y, **Dixon DL**, Jones RM, Salgado TM. Impact of clinical pharmacy services on the achievement of diabetes- and hypertension-related quality measures. American College of Clinical Pharmacy Annual Meeting (virtual). October 2020.

24. Marawan A, Thomas GK, Canada JM, Billingsley H, **Dixon DL**, Van Tassell B, Kadariya D, Markley R, Rotelli B, Shah KB, Celi F, Abbate A, Carbone S. Edema Index Predicts Cardiorespiratory Fitness in Patients with Heart Failure with Reduced Ejection Fraction and Type 2 Diabetes Mellitus. Heart Failure Society of America Annual Meeting (virtual); October 2020. *J Card Fail.* 2020;26(10):S48-S49.
25. Marawan A, Thomas G, Billingsley H, Kadariya D, **Dixon D**, Markley R, Trankle C, Wohlford G, Chiabrando J, Vecchié A, Van Tassell B, Arena R, Abbate A, Carbone S. Bioelectrical Impedance Analysis Identifies Patients With Worse Cardiorespiratory Fitness In Heart Failure With Reduced Ejection Fraction And Type 2 Diabetes Mellitus. Heart Failure Society of America Annual Meeting (virtual); October 2020; *J Card Fail.* 2020;26(10):S48-49.
26. *Khaddage S, Patterson J, **Dixon DL**. Sex and Age Differences in Ambulatory Blood Pressure Monitoring Tolerability. American Heart Association Hypertension Scientific Sessions; Virtual Meeting; September 10, 2020. *Hypertension.* 2020;76(Suppl_1):AP166. https://doi.org/10.1161/hyp.76.suppl_1.P166.
27. **Dixon DL**, Simmons G, Rodriguez L, Abbate A. An interdisciplinary approach to managing severe hyperlipidemia in a patient with graft versus host disease of the liver. American College of Cardiology Annual Scientific Session; Chicago, IL; March 2020 (virtual). *J Am Coll Cardiol.* 2020;74(11, Suppl 1): DOI: 10.1016/S0735-1097(20)32925-9.
28. **Dixon DL**, Patterson J, Gatewood S, Kaefer T, Jadallah J, Curtis M, Hawkey L, Grigsby J, Salgado TM, Holdford D. Implementation and Evaluation of a 24-Hour Ambulatory Blood Pressure Monitoring Service in Community Pharmacy. American Pharmacists Association Annual Meeting (virtual); Washington, DC; March 2020.
29. Jia X, Ramsey DJ, al Rifai M, Ahmed ST, Akeroyd JM, **Dixon DL**, Gluckman T, Nambi V, Ballantyne CM, Petersen LA, Stone NJ, Virani SS. Lipid Monitoring and Treatment Intensification of Cholesterol Lowering Therapies - Insight from the Veterans Affairs Healthcare System. American Heart Association Scientific Sessions; Philadelphia, PA; November 16, 2019.
30. *Bhagat S, *Khaddage S, Baker WL, Koenig RA, Salgado TM, Kelly M, **Dixon DL**. Impact of Pharmacist Interventions on Reducing Low--Density Lipoprotein Cholesterol (LDL-C) Levels: A Systematic Review and Meta--Analysis of Randomized Controlled Trials. American College of Clinical Pharmacy Annual Meeting; New York City, NY; October 26, 2019.
31. Wohlford GF, Ho A, Dell M, Vecchie A, Buckley LF, **Dixon DL**, Van Tassell BW. Predicting hospitalizations for heart failure using measurements of atmosphere and atmosphere quality. American College of Clinical Pharmacy Annual Meeting; New York City, NY; October 26, 2019.
32. Ho A, Wohlford GF, Vecchie A, Dell M, **Dixon DL**, Van Tassell BW. The relationship of air pollutants and heart failure hospitalizations in a medium-sized metropolitan city in Virginia. American College of Clinical Pharmacy Annual Meeting; New York City, NY; October 26, 2019.
33. *Hess D, *Seto S, Nadpara, Sisson EM, **Dixon DL**. Characterization of Familial Hypercholesterolemia Management at an Academic Medical Center. National Lipid Association Scientific Sessions; Miami, FL; May 2019. *J Clin Lipidol.* 2019;13(3):e39-e40.
34. Billingsley H, Carbone S, Canada J, Buckley L, **Dixon D**, Kadariya D, Wohlford G, Trankle C, Van Tassell B, Abbate A. Omega-3 Red Blood Cell Count is Associated with Fat Mass Index and Leptin in Subjects with Obesity and Heart Failure with Preserved Ejection Fraction. American Society of Nutrition Annual Meeting; Baltimore, MD; June 2019. *Curr Dev Nutr.* 2019 Jun 13;3(Suppl 1). pii: nzz041.P21-001-19.

35. Wohlford GF, Contaifer D, Buckley LF, **Dixon DL**, Price ET, Canada JM, Abbate A, Wijesinghe D, Van Tassell BW. Pathophenotype Development for Patients with Recently Decompensated Heart Failure. American College of Cardiology Scientific Sessions; New Orleans, LA; March 2019. *J Am Coll Cardiol*. 2019;73(9, Suppl 1):979.
36. Fatani N, **Dixon DL**, Van Tassell BW, Buckley LF, Fanikos J. Longer Time in Therapeutic Blood Pressure Range Protects Against Major Adverse Cardiovascular Events and All-Cause Mortality in Patients with Hypertension: A Post-hoc Analysis of SPRINT. American Heart Association Scientific Sessions; Orlando, FL; November 2018. *Circulation*. 2018;138 (Suppl 1):A14190. **Selected for Oral Presentation**
37. **Dixon DL**, Parod ED, Sisson EM, Van Tassell BW, Nadpara P, Dow A. Pharmacist Physician Collaborative Care Model vs. Standard Care: Assessing Time in Therapeutic Range in Patients with Hypertension. American College of Clinical Pharmacy Global Conference; Seattle, WA; October 22, 2018. *J Am Coll Clin Pharm*. 2018;1:135.
38. Wohlford GF, Buckley LF, **Dixon DL**, Baker WL, Van Tassell BW. Antidepressant use in TOPCAT America's. Heart Failure Society of America Annual Meeting; Nashville, TN; September 15, 2018. *J Card Fail*. 2018;24(8S):S60-S61.
39. Caldas LM, Basco H, Barthlow M, Funn D, Salgado TM, **Dixon DL**, Sisson EM. Student Pharmacist-Led Implementation of the National Diabetes Prevention Program in an Urban-Free Clinic. Association of Diabetes Care & Education Specialists Annual meeting; Baltimore, MD; August 18, 2018.
40. Donohoe KL, Van Tassell BW, Hylton-Gravatt LA, Brophy DF, Brophy GM, Bucheit JD, Caldas L, Crouse EL, **Dixon DL**, Flurie R, Gatewood SS, Goode JVR, Grecheck L, Kirkwood C, Matulewicz AT, McRae MP, Morgan LM, Omecene N, Pakyz AL, Powers KE, Peron EP, Sisson E, Slattum PW, Washington CS, Yunker NS, Zimmerman K. Evaluation of Disease State Topics Taught in a Doctor of Pharmacy Curriculum Using the ACCP Toolkit. American Association of Colleges of Pharmacy Annual Meeting; Boston, MA; July 22, 2018. *Am J Pharm Educ*. 2018;82(5):510.
41. Bajaj S, Lajthia E, **Dixon DL**, Salgado TM. Pharmacy Practice Innovation Research Centers Across the United States. American Pharmacists Association Annual Meeting; Nashville, TN; March 2018. *J Am Pharm Assoc*. 2018;58(2):e182.
42. Van Tassell BW, Wohlford G, Kim F, Canada J, Carbone S, Kadariya D, Billingsley H, Trankle C, Buckley L, **Dixon D**, Viscusi M, Del Buono M, Medina H, Arena R, Abbate A. Interleukin-1 Blockade Reduces Patient Perceptions of Exertion and Dyspnea Among Patients with Recently Decompensated Systolic Heart Failure: A Subgroup Analysis of the REDHART Trial. American College of Cardiology Scientific Sessions; Orlando, FL; March 2018. *J Am Coll Cardiol*. 2018;71(11): Suppl 1: A968.
43. Van Tassell B, Canada J, Buckley L, Carbone S, Trankle C, Del Buono M, **Dixon D**, Kadariya D, Billingsley H, Park TS, Vo Chau, Dessie S, Arena R, Abbate A. Interleukin-1 Blockade in Heart Failure with Preserved Ejection Fraction: The Diastolic Heart Failure Anakinra Response Trial 2 (DHART2). American Heart Association Scientific Sessions; Anaheim, CA; November 2017. *Circulation*. 2017;136 (Suppl 1):A177709.
44. *Buckley LF, **Dixon DL**, Wohlford GF, Wijesinghe D, Baker WL, Van Tassell BW. Intensive Blood Pressure Control in Patients with and without Type 2 Diabetes Mellitus: An analysis of SPRINT and ACCORD BP. American College of Clinical Pharmacy Annual meeting; Phoenix, AZ; October 2017. *Pharmacotherapy*. 2017;37(12):e143. **Best Resident/Fellow Poster Award**
45. Carbone S, Canada JM, Buckley LF, Trankle C, Giuseppe MG, **Dixon DL**, Kiadariya D, Billingsley H, Park TS, Vo C, Dessie SA, Buzzetti R, Arena R, Van Tassell BW, Abbate A. BMI is an Independent Determinant of

Exercise Intolerance in Obese Patients with HFpEF. Obesity Week Annual Conference. Washington, DC; November 2, 2017.

46. *Helsing H, Taylor P, **Dixon D**. Practice Patterns for Addressing LDL-Cholesterol Levels Below 40 in Patients Receiving Statin Therapy. National Lipid Association Annual Scientific Sessions; Philadelphia, PA; May 2017. *J Clin Lipidol*. 2017; 11(3):835. American College of Clinical Pharmacy Virtual Poster Symposium; May 2017. *Pharmacotherapy*. 2017;37(6):e40.
47. *Parod E, **Dixon DL**, Sisson E, Nadpara P, Van Tassell B, Carl D, Dow A. Comparison of a Pharmacist-Physician Collaborative Care Model to Standard Care on the Time to Reach Goal Blood Pressure for Patients with Hypertension. American College of Cardiology Annual Meeting; Washington, DC; March 2017. *J Am Coll Cardiol*. 2017; 69(Suppl II):2566.
48. **Dixon DL**, Parod E, Sisson E, Nadpara P, Van Tassell B, Carl D, Dow A. Comparison of a Pharmacist-Physician Collaborative Care Model to Standard Care on the Time to Reach Goal Blood Pressure for Patients Presenting with Urgent Hypertension. American College of Cardiology Annual Meeting; Washington, DC; March 2017. *J Am Coll Cardiol*. 2017; 69(Suppl II):1837.
49. **Dixon DL**, Trankle C, Buckley L, Carbone S, Abbate A. Management of Obesity in Patients with Diastolic Dysfunction. American College of Cardiology Annual Meeting; Washington, DC; March 2017. *J Am Coll Cardiol*. 2017; 69(Suppl II):2106.
50. Buckley LF, Carbone S, Canada J, Trankle C, Christopher S, Regan J, Viscusi MM, **Dixon DL**, Abouzaki A, Kadariya D, Arena R, Abbate A, Van Tassell B. Arterial elastance drives ventilator inefficiency in systolic heart failure. American College of Cardiology Annual Meeting; Washington, DC; March 2017. *J Am Coll Cardiol*. 2017; 69(Suppl II):746.
51. Trankle C, Canada J, Buckley L, Carbone S, **Dixon D**, Arena R, Van Tassell B, Abbate A. Early diastolic mitral annular velocity at peak exercise determines peak aerobic exercise capacity in heart failure with preserved ejection fraction. American College of Cardiology Annual Meeting; Washington, DC; March 2017. *J Am Coll Cardiol*. 2017; 69 (Suppl II):889.
52. Carbone S, Canada JM, Buckley LF, Trankle CR, Billingsley H, Dessie S, Kadariya D, Abouzaki NA, Thurber C, **Dixon D**, Buzzetti R, Van Tassell BW, Abbate A. Sugar consumption predicts impaired cardiorespiratory fitness in patients with heart failure with preserved ejection fraction. ASPEN Nutrition Science and Practice Conference; Orlando, FL; January 2017. *J Parenter Enteral Nutr*. 2017;41(2): Suppl 1: 266-300.
53. Billingsley H, Carbone S, Buckley L, **Dixon D**, Kadariya D, Dessie S, Van Tassell BW, Abbate A, Siddiqui M. Dietary polyunsaturated fatty acid consumption is associated with improved body composition in nonalcoholic steatohepatitis patients. Association for Clinical and Translational Science Annual Meeting; Washington, DC; April 2017. *J Clin Transl Sci*. 2017;1(Suppl 1):38.
54. Buckley L, Carbone S, Trankle C, Viscusi MM, Regan J, **Dixon D**, Abouzaki N, Christopher S, Billingsley H, Kadariya D, Arena R, Abbate A, Van Tassell B. Ventriculo-arterial coupling and left ventricular mechanical work in systolic and diastolic heart failure. Association for Clinical and Translational Science Annual Meeting; Washington, DC; April 2017; *J Clin Transl Sci*. 2017;1(Suppl 1):36.

55. *Parod E, **Dixon D**, Sisson E, Ogbonna K. A case report of complete warfarin resistance and clinical application of pharmacogenetic testing. American College of Clinical Pharmacy Annual Meeting; Hollywood, FL; October 2016. *Pharmacotherapy*. 2016; 36(12):e297.
56. *Parod E, **Dixon D**, Sisson E, Nadpara P, Moczygamba L, Carl D, Dow A. Pharmacist-physician collaborative care model vs. standard care: assessing time to blood pressure goal. American College of Clinical Pharmacy Virtual Poster Symposium; May 2016. *Pharmacotherapy*. 2016;36(7):e112.
57. **Dixon DL**, Sisson EM, Parod E, Kelly M. Nighttime Dosing of Amlodipine vs. Lisinopril in Non-Dipping African Americans - an Interim Analysis. American Association of Colleges of Pharmacy Annual Meeting; Anaheim, CA; July 2016. *Am J Pharm Educ*. 2016;80(5) Article S2:119.
58. Chennault R, Touchette D, Ford KD, Capitano B, Welch V, Beck B, Bergman S, Bishop W, Bolesta K, Bratberg J, Cleary J, Das RP, Depcinski SC, **Dixon DL**, Engle A, Estrada SJ, Hachey Dm, Haftmann R, Hayney M, Hebner J, Hughes B, Ikwuagwu JO, Irwin AN, Jantz J, Jen SP, Krause T, Kuhn S, Lamb K, Liewer SE, McCoy C, McGuffey G, McKeen JT, McManus D, Morell J, Murray KP, Olin JL, Painter NA, Parish T, Peppard WJ, Porath A, Rudd KM, Swierz, Tran M, Wardlow LC, Wdowiarz K, White M, Yancey AM, Yeung SYA, Zarowitz BJ. American College of Clinical Pharmacy Practice-Based Research Network Collaborative: Navigating Institutional Review Board Challenges in a Clinical Pharmacy Practice-Based Research Study. North American Primary Care Research Group Practice-Based Research Network Conference; Bethesda, MD; June 29, 2015.
59. Kiser K, Haines S, **Dixon DL**, Tran A. iForumRx – Utilizing the World Wide Web to Connect Ambulatory Care Pharmacists. American College of Clinical Pharmacy Global Conference on Clinical Pharmacy; San Francisco, CA; October 2015. *Pharmacotherapy*. 2015; 35(11): e228-e229.
60. Sicat BL, **Dixon DL**, Bishop S, Lee B, Rybarczyk B, Stewart K, Wolver S, Phillips A. Interprofessional Team-Based Learning in a Primary Care Teaching Clinic: Focus on Obesity. American Association of Colleges of Pharmacy Annual Meeting; National Harbor, MD; July 2015. *Am J Pharm Educ*. 2015;79(4):63.
61. **Dixon DL**, Sisson EM, Shuford VP, Harpe SE. Use of Video Recorded Clinic Visits to Improve Assessment of Student Pharmacist Clinical Interviewing Skills. American Association of Colleges of Pharmacy Annual Meeting; Grapevine, TX; July 2014. *Am J Pharm Educ*. 2014; 78(5):138.
62. *Bucheit J, Sisson E, **Dixon DL**. Ambulatory blood pressure monitoring for measuring the effectiveness of amlodipine and hydrochlorothiazide in treating urgent and stage 2 hypertension. American College of Clinical Pharmacy Virtual Poster Symposium. *Pharmacotherapy*. 2014; 34(6): e101.
63. *Ayele S, *Case B, *Dane K, *Jafari N, *Robinson M, *Tran N, Sisson E, **Dixon DL**. Validation of the Medication Adherence Individual Review Screening Tool in Underserved Adult Patients. American Society of Health-System Pharmacists Mid-Year Meeting; Anaheim, CA; December 2014.
64. Sisson E, **Dixon DL**, Kildow C. Evaluation of Comprehensive Medication Management in a Safety Net Clinic. Association of Diabetes Care & Education Specialists Annual Meeting; Orlando, FL; August 2014.
65. *Kelly M, **Dixon DL**. Interim Results from a Cardiologist-Pharmacist Collaboration to Improve Blood Pressure in an Ambulatory Cardiology Clinic. American College of Clinical Pharmacy Annual Meeting; Albuquerque, NM; October 2013. *Pharmacotherapy*. 2013; 33(10): e271.
66. *Scott A, Sisson E, Pakyz A, **Dixon DL**. Evaluation of Cardiometabolic Risk in an Underserved Population. American Society of Health-System Pharmacists Mid-Year Meeting; Orlando, FL; December 2013.

67. Williams V, **Dixon DL**, Barnette D, Beardsley J. Healthy Outcome Partnership for Employees with diabetes (HOPE): Evaluation of an Employer-Sponsored Diabetes Management Program. American College of Clinical Pharmacy Spring Practice & Research Forum; Charlotte, NC; April 2010. *Pharmacotherapy*. 2010;30(4): e153.

Local and Regional (n = 7)

1. *Grigsby J, Patterson J, Gatewood S, Kaefer T, Jadallah J, Curtis M, Hawkey L, Salgado TM, Holdford D, **Dixon DL**. Development of a 24-Hour Ambulatory Blood Pressure Monitoring Service in Community Pharmacy. 8th Annual Jewell and Carl F. Emswiler Interprofessional Symposium; Richmond, VA; February 29, 2020.
2. Morales J, Suarez N, Garcia J, Caldas L, Matulewicz A, Orengo S, Murchie M, Crossman S, Salgado T, **Dixon D**, Bucheit J. Comparison of Blood Pressure Control Rates in Patients with Type 2 Diabetes Mellitus Seen in an Interprofessional Clinic versus National Data. 8th Annual Jewell and Car F. Emswiler Interprofessional Symposium; Richmond, VA; February 29, 2020.
3. Trankle C, Carbone S, Canada JM, *Buckley L, **Dixon DL**, Buzzetti R, Arena R, Van Tassell B, Abbate A. Obesity Contribute to Exercise Intolerance in Heart Failure with Preserved Ejection Fraction. Mid-Atlantic Capital Cardiology Symposium; Washington, DC; November 2016.
4. Sisson EM, **Dixon DL [Presenter]**, Kildow C, Van Tassell B, Carl DE, Varghese D, Electricwala B, Carroll N. Pharmacist Physician Collaboration to Improve Blood Pressure Control in an Inner City Safety-Net Clinic. Third Annual Jewell and Carl F. Emswiler Interprofessional Symposium; Richmond, VA; April 2015.
5. **Dixon DL**, Sicat BL, Bishop S, Lee B, Rybarczyk B, Stewart K, Wolver S, Phillips A. Interprofessional Team-Based Learning in a Primary Care Teaching Clinic: Focus on Obesity. 3rd Annual Jewell and Carl F. Emswiler Interprofessional Symposium; Richmond, VA; April 2015.
6. Thomas CS, Trankle CR, Carbone S, Oddi C, Abouzaki NA, Turlington J, Melchior RD, **Dixon D**, Van Tassell BW, Abbate High risk clinical features of patients with systolic heart failure upon discharge after an episode of acute decompensation (from the VCU-RED-HEART Pilot data). Mid Atlantic Capital Cardiology Symposium; Washington, DC; November 2014.
7. Crossman S, Stevens M, Ryan M, Mack D, **Dixon DL [Presenter]**. Interprofessional Global Service Learning Through HOMBRE (Honduras Outreach Medical Brigade Relief Effort). 1st Annual Jewell and Carl F. Emswiler Interprofessional Symposium; Richmond, VA; April 2013.

INVITED PRESENTATIONS

International (n =2)

1. **[Panelist]** *The Lp(a) Challenge in Primary Care: Who to Screen, Why it Matters, and What to Do Next*. A to Z of Cardiovascular Pharmacotherapy Series (Virtual). International Society of Cardiovascular Pharmacotherapy. December 3, 2025.
2. *Cholesterol Vaccines or Extravagant Injectable Medications? An Update for Pharmacists*. PharmaCEries Webinars (Virtual). Cleveland Clinic Abu Dhabi, UAE; June 21, 2022.

National (n = 53)

1. *Overview of the 2025 AHA/ACC Guidelines on High Blood Pressure*. HeartBeat California Program, California Department of Health (Webinar). July 15, 2026.
2. *Overview of the 2026 AHA/ACC/Multi-Society Dyslipidemia Guidelines*. HeartBeat California Program, California Department of Health (Webinar). July 15, 2026.
3. *Current and Future Pharmacologic Treatments for Hypertriglyceridemia*. Mastering Triglyceride Science: An In-Depth Master's Course, National Lipid Association Scientific Sessions; Chicago, IL. June 11, 2026.
4. *The ADA's Standards of Care in Diabetes: 2026 Updates (Cardiovascular Disease and Risk Management)*. American Diabetes Association Scientific Sessions; New Orleans, LA. June 6, 2026.
5. *Under Pressure: Implementing Pharmacy-Based Hypertension Services*. American Pharmacists Association Annual Meeting; Los Angeles, CA; March 29, 2026.
6. *Beyond the Lipid Panel: Exploring the Frontier of Lipid Biomarkers in Cardiovascular Disease Prevention*. Geisinger Health System Pharmacy Grand Rounds; June 14, 2024.
7. **[Moderator]** *Balancing the Scale: Unveiling the Truth about Weight loss Pharmacotherapy- Use Misuse, and Effective Strategies*. American College of Cardiology Scientific Sessions; Atlanta, GA; April 6, 2024.
8. *Practical Approaches to Navigating Statin-Associated Side Effects and Intolerance*. MonteHeart Imaging and Clinical Lectures. Einstein Montefiore Center for Continuing Medical Education (Virtual). March 22, 2024.
9. **[Panelist]** *"ABCDs" of Managing Chronic Coronary Disease: Emerging Recommendations*. Prescriber's Letter and Pharmacist's Letter (Webinar); September 18, 2023.
10. *Medication Conundrum Cases*. American College of Cardiology Scientific Sessions; New Orleans, LA; March 2023.
11. *Inclisiran: When and How Should We Use It?* American College of Cardiology Scientific Sessions; New Orleans, LA; March 2023.
12. *Overview of New Pharmacologic Therapies for Heart Failure*. American College of Cardiology Scientific Sessions; Washington, DC; April 2022.
13. *Therapeutic Inertia: Strategies to Achieve Treatment Goals Utilizing Team Based Care*. American College of Cardiology Scientific Sessions; Washington, DC; April 2022.
14. **[Panelist]** *Finding the Sweet Spot for SGLT2 and GLP-1 Use in Cardiovascular Prevention*. American College of Cardiology Scientific Sessions; Washington, DC; April 2022.
15. Co-presented with Joseph Saseen, PharmD. *Old Drugs, New Drugs, and New Evidence for Dyslipidemia Management*. American Society of Health System Pharmacists Midyear Clinical Meeting (Virtual); December 2021.
16. **[Moderator]** *A Cornucopia of Cardiovascular Therapies: Ripe for the Picking or Too Much of a Good Thing?* American College of Clinical Pharmacy Annual Meeting (Virtual); November 17, 2021.
17. *Pharmacotherapy for Weight Loss: When and How*. American College of Cardiology Scientific Sessions (Virtual); May 2021.

18. *Under Pressure: How to Write Recommendation Letters that Stand Out from the Pack*. American College of Clinical Pharmacy Spring Forum (Virtual); April 2021.
19. *Scholarship in the 21st Century: Optimizing Reach, Engagement, and Impact*. American College of Clinical Pharmacy Annual Meeting (Virtual); October 2020.
20. Co-Presented with Mark Cziraky, PharmD, Lynne Braun, NP, and Harold Bayes, MD. *Tailoring Lipid-Lowering Therapy to Meet Individualized Goals*. A Medscape Live! Event (Webinar); September 10, 2020.
21. Co-Presented with Joseph Saseen, PharmD and Karen Aspry, MD. *Lipid Logic – Guess the Answer: An Interactive Audience Session*. National Lipid Association (Webinar); September 10, 2020.
22. *Cardiovascular Patient Management in the Era of COVID-19*. National Lipid Association (Webinar); May 22, 2020.
23. *Increasing Access to 24-hour Ambulatory Blood Pressure Monitoring Through Community Pharmacies*. American Pharmacists Association Meeting; Washington, DC; March 21, 2020. **(Conference canceled due to COVID-19)**
24. *Overview of Pre-DM and Metabolic Syndrome and ASCVD Risk*. American College of Cardiology Annual Scientific Session; Chicago, IL; March 29, 2020. **(Conference canceled due to COVID-19)**
25. *Pharmacology for The Clinician: SGLT-2 Inhibitors & GLP-1 Agonists*. American College of Cardiology Annual Scientific Session; Chicago, IL; March 28, 2020. **[Session Co-Chair] (Conference canceled due to COVID-19)**
26. *Evaluating the Updated 2018 ACC/AHA Cholesterol Guidelines*. American College of Clinical Pharmacy Annual Meeting; New York City, NY; October 27, 2019.
27. *Navigating the Jungles of Vascular Outcomes*. American College of Clinical Pharmacy Annual Meeting; New York City, NY; October 26, 2019.
28. *Understanding the Real-World Uses of Drug Interaction Information*. U.S. Food & Drug Administration Section 7 Labeling: Enhancing the Accessibility and Utility of Drug Interaction Information Private Stakeholder Workshop; Washington, DC; October 16, 2019. Organized by the Duke-Margolis Center for Health Policy. Policy brief from the workshop published [online](#).
29. *Implementation of Team-Based Strategies to Improve Hypertension Outcomes*. 3rd Annual University of Utah Translational Hypertension Symposium and Early Stage Investigator Workshop; Salt Lake City, Utah; October 10, 2019. Sponsored by the National Heart, Lung, and Blood Institute (R13HL144012-2).
30. **[Moderator]** *Mythbusters in Clinical Lipidology – Pharmacotherapy Debunked*. National Lipid Association Annual Scientific Sessions; Miami, FL; May 18, 2019.
31. *State of the Art Case-Based Lecture: Individualizing the Process of Prescribing Through Shared-Decision Making*. American College of Cardiology Annual Meeting; New Orleans, LA; March 16, 2019.
32. *Risk-Based Hypertension Management: It's All About Context!* American College of Cardiology Annual Meeting; New Orleans, LA; March 16, 2019.
33. *How Well Do You Know Your Drug-Drug Interactions? A Case-Based Lecture*. American College of Cardiology Annual Meeting; New Orleans, LA; March 17, 2019.

34. *An Evidence-Based Approach to Using Social Media to Enhance Your Scholarly Career*. American College of Clinical Pharmacy Global Conference on Clinical Pharmacy; Seattle, WA; October 23, 2018.
35. *Establishing Your Digital Profile: Your Guide to Twitter and LinkedIn*. American College of Clinical Pharmacy Global Conference on Clinical Pharmacy; Seattle, WA; October 22, 2018.
36. Co-presented with Melissa Magwire, RN and Lauren Pamulapati, PharmD. *Contemporary Approaches to Managing Diabetes in Individuals with Cardiovascular Disease*. Association of Diabetes Care & Education Specialists Annual Meeting; Baltimore, MD; August 19, 2018.
37. Co-presented with Amber Martirosov, PharmD. *PCSK9 Inhibitors: Appropriate Use in Patients with Atherosclerotic Cardiovascular Disease*. American Society of Health-System Pharmacists Summer Meeting; Denver, CO; June 3, 2018.
38. *Dyslipidemia*. Cardiology Pharmacy Preparatory Review Course. American College of Clinical Pharmacy Updates in Therapeutics; Jacksonville, FL; February 16, 2018.
39. *Managing Diabetes in Patients with Cardiovascular Disease and Heart Failure*. Novo Nordisk Diabetes Educator Training Program provided by the Association of Diabetes Care & Education Specialists (Webinar); December 1, 2017.
40. *New Technologies in Development for Targeting PCSK9: What's on the Horizon?* National Lipid Association Clinical Lipid Update Meeting; Indianapolis, IN; August 12, 2017.
41. **Co-Session Chair** with Joyce Ross, NP. *Back to the Future: Clinical Experience with and Access to Lipid-Lowering Agents of the Past, Present, and Future*. National Lipid Association Expert Discussion and Town Hall. Scientific Sessions Meeting; Philadelphia, PA; May 18, 2017.
42. *Therapeutic Options for Managing Hypertriglyceridemia*. National Lipid Association Clinical Lipid Update Meeting; Amelia Island, FL; August 26, 2016.
43. *Nuts and Bolts of the New Anti-Obesity Drugs and Which One for Who? Pharmacology, Drug-Drug Interactions, and Efficacy*. American College of Cardiology Annual Meeting; Chicago, IL; April 3, 2016.
44. *Team-Based Care Cardiovascular Care: A Unified Vision to Improve Patient Care*. American College of Cardiology Scientific Sessions; Chicago, IL; April 3, 2016.
45. *Latest Developments in Insulin Therapy*. Association of Diabetes Care & Education Specialists (Webinar); August 19, 2015.
46. Co-Presented with Evan Sisson, PharmD. *Lipid Guidelines: What is Best for My Patient?* Association of Diabetes Care & Education Specialists Annual Meeting; New Orleans, LA; August 5, 2015.
47. *Endocrine Update*. American Society of Consultant Pharmacists Certified Geriatric Pharmacist Exam Preparation and Recertification Boot Camp; Baltimore, MD; August 1, 2015.
48. *Cardiovascular Update*. American Society of Consultant Pharmacists Certified Geriatric Pharmacist Exam Preparation and Recertification Boot Camp; Baltimore, MD; August 1, 2015.

49. Co-Presented with Andrew Bzowickyj, PharmD, Ginah Nightingale, PharmD, Mary Vilay, PharmD. *Tips on Being a Successful New Investigator Award Recipient*. American Association of Colleges of Pharmacy (Webinar); June 10, 2015.
50. Co-Presented with Frank Zieve, MD. *Dyslipidemia in FQHCs: Rising to the Challenge*. National Lipid Association (Webinar); March 16, 2015.
51. *Use of Video Recorded Clinic Visits to Improve Assessment of Student Pharmacist Clinical Interviewing Skills*. American Association of Colleges of Pharmacy Annual Meeting; Grapevine, TX; July 29, 2014.
52. **[Moderator]** *Case Based Workshop: Atrial Fibrillation Monitoring and Management*. National Association of Specialty Pharmacy (Webinar); March 26, 2014.
53. Co-Presented with Evan Sisson, PharmD. *New Lipid Guidelines, Were they Worth the Wait?* Association of Diabetes Care & Education Specialists Annual Meeting; Philadelphia, PA; August 8, 2013.

Local and Regional (n = 38)

1. *Lipid Management Across the Lifespan*. 1st Annual CVD Medicine for the Primary Care Provider Conference; Richmond, VA; April 11, 2026.
2. *Class II Therapies in Heart Failure: Undervalued Tools or Justly Overlooked?* 3rd Annual Advanced Practice Provider Heart Failure Conference; Richmond, VA; September 27, 2025.
3. *Heart Failure Epidemiology and Outcomes Statistics*. Heart Failure Consortium in Virginia Advanced Heart Failure Symposium; Richmond, VA; October 26, 2024.
4. *Evaluation and Management of Dyslipidemia Over a Woman's Life Cycle*. Heart Health in Women Symposium; Richmond, VA; February 3, 2024.
5. *Clinical Management of Heart Failure in 2023: Guideline Updates*. A Contemporary Approach to Heart Failure: Updates for the Cardiology Advanced Practice Provider; Richmond, VA; November 18, 2023
6. *Dyslipidemia Management in Women Requires a Scalpel, not a Sledgehammer*. Heart Health in Women 2022 Conference; Richmond, VA; February 5, 2022.
7. *A Brief Review of the 2021 ADA Standards of Medical Care for Diabetes*. Practical Endocrine Topics for Primary Care (Virtual); June 5, 2021.
8. *Diabetes Management for the Cardiologist: No Longer Taboo!* Cardiology Fellow Case Conference. VCU Medical Center; Richmond, VA; October 6, 2020.
9. *Overview of Pharm.D. Education and Training for HB1506*. Commonwealth of Virginia Board of Pharmacy Statewide Protocol Workgroup Meeting (Virtual); August 3, 2020.
10. Co-presented with Ajay Pillai, MD and Antonio Abbate, MD. *Cardiovascular Manifestations of COVID-19*. Hospitalist Grand Rounds. VCU Medical Center; Richmond, VA; April 30, 2020. Encore presentation on May 18, 2020.

11. *Utilization of Pharmacy Residents and Dietetic Interns to Deliver a Diabetes Prevention Program to Underserved Patients*. 8th Annual Jewell and Car F. Emswiler Interprofessional Symposium; Richmond, VA; February 29, 2020.
12. *APhA Pharmacy-Based Cardiovascular Disease Risk Management Course*. Virginia Pharmacists Association Annual Meeting; Virginia Beach, VA; August 18, 2019.
13. Co-presented with Stephanie Mayer, MD. *Update on clinical management of hyperlipidemia*. Practical Endocrine Topics for Primary Care Symposium. Richmond, VA; June 8, 2019.
14. Co-presented with Stephanie Mayer, MD. *Type 2 diabetes management beyond A1c – oral medications and non-insulin therapy*. Practical Endocrine Topics for Primary Care Symposium. Richmond, VA; June 8, 2019.
15. Co-presented with Leticia Moczygemba, PhD. *Implementation Strategies*. 7th Annual Jewell and Carl F. Emswiler Interprofessional Symposium: Pre-Conference on Best Practices for Implementing Team Based Primary Care. Richmond, VA; February 1, 2019.
16. *Elevated Triglycerides and Residual Cardiovascular Risk: Much Ado About Nothing?* Cardiology Grand Rounds. VCU Medical Center; Richmond, VA; August 9, 2018.
17. *Which non-statin (if any) is right for my patient?* Pharmacotherapy Grand Rounds. VCU Medical Center; Richmond, VA; February 1, 2018.
18. *Update in Cardiovascular Pharmacotherapy*. Virginia Association of Clinical Nurse Specialists Annual Pharmacology Conference; Richmond, VA; September 29, 2017.
19. *Dyslipidemia Management: Past, Present, and Future*. Cardiology Grand Rounds. VCU Medical Center; Richmond, VA; August 17, 2017.
20. Co-Presented with Salvatore Carbone, MS and Antonio Abbate, MD, PhD. *SGLT2 Inhibitors for the Prevention of Cardiovascular Events in Diabetes*. Department of Internal Medicine Grand Rounds. VCU Medical Center; Richmond, VA; May 22, 2017.
21. *2013 ACC/AHA Cholesterol Guideline: Has the dust finally settled?* Cardiology Grand Rounds. VCU Pauley Heart Center; Richmond, VA; August 25, 2016.
22. **[Panelist]** *Reflections on Current Admissions Practices*. VCU Health Admissions Symposium; Richmond, VA; May 23, 2016.
23. *Contemporary Diabetes Management: “Out with the Old, in with the New?”* Cardiology Case Conference. VCU Pauley Heart Center; Richmond, VA; May 12, 2016.
24. **[Panelist]** *Clinician or Researcher: Why not both?* Ready, Set, Grant! Workshops on Competitive Grant Writing. VCU Health System; Richmond, VA; January 12, 2016.
25. Co-Presented with Lana Konigsberg, PharmD. *Educational Roundtable Discussion: Familial Hypercholesterolemia*. Sponsored by Sanofi U.S.; Richmond, VA; October 13, 2015.
26. *Review of ACC/AHA Guidelines on Lipid Management*. VCU Pauley Heart Center Core Conference for Cardiology Fellows; Richmond, VA; August 18, 2015.

27. **[Panelist]** *The Voices of Primary Care Collaborators*. VCU Department of Family Medicine and Population Health, Student Family Medicine Association; Richmond, VA; October 11, 2014.
28. Co-Presented with Lana Konigsberg, PharmD. *Educational Roundtable Discussion: Unmet Needs in Hyperlipidemia*. Sponsored by Sanofi U.S.; Richmond, VA; August 7, 2014.
29. *Implications of the 2013 Cholesterol Guideline...Myth vs. Reality*. Virginia Pharmacists Association 133rd Annual Convention; Virginia Beach, VA; August 4, 2014.
30. *The Quandary of QT_c Prolongation*. 25th Annual Virginia Geriatrics Conference; Richmond, VA; April 25, 2014.
31. Co-Presented with Lana Konigsberg, PharmD. *Educational Roundtable Discussion: Unmet Needs in Hyperlipidemia*. Sponsored by Sanofi U.S.; Richmond, VA; April 8, 2014.
32. *Hypertension Treatment Across the Lifespan*. Virginia Dietetic Association Meeting; Richmond, VA; April 7, 2013.
33. *Implications of the 2013 ACC/AHA Lipid Management Guidelines*. Campbell University College of Pharmacy & Health Sciences Alumni Event; Concord, NC; March 2, 2014.
34. *Update on Lipid Management – Where are we now?* Virginia Chapter of the American College of Cardiology, Annual Meeting; Richmond, VA; October 4, 2013.
35. *Management of Hypertension Across the Lifespan*. VCU Health System Advanced Practice Nurse Conference; Richmond, VA; April 19, 2013.
36. **[Panelist]** *If I Knew Then What I Know Now: Sound Advice from Early Career Faculty*. VCU Center for Teaching Excellence; Richmond, VA; August 12, 2013.
37. Co-Presented with Kristin Duffey, PharmD. *2007 New Drug Update*. Western NC Pharmacy Association; Asheville, NC; February 18, 2007.
38. *A Review of Hypertension*. Mountain Area Health Education Center; Asheville, NC; September 2006.

ONLINE AND TRADE JOURNAL PUBLICATIONS (*mentee)

1. St. Peter WL, Neumiller JJ, Dixon DL, Spinler SA. Breaking down silos of care to optimize management of cardiovascular-kidney-metabolic syndrome. *Cardiology Today*. [Available here](#). December 29, 2025.
2. Jones PH, Wilson DP, **Dixon DL**, Deville C. NLA's Future Education Endeavors. *Lipid Spin: Here and Now*. 2022; 2-4.
3. **Dixon DL**, Underberg J. The Future of NLA Scientific Statements: To Infinity and Beyond! *Lipid Spin: Here and Now*. 2022; 12-13.
4. *Gaine SP, Kulkarni A, **Dixon DL**, Patel J. Expert Analysis: NLA 2022 Definition of Statin Intolerance. American College of Cardiology. [Available here](#). Aug 17, 2022.
5. *Farbaniec M, Hartz J, Singh A, **Dixon DL**. Expert Analysis: Utilization of Clinical Testing in the Setting of Dyslipidemia. American College of Cardiology. [Available here](#). Nov 22, 2021.

6. *Sharif M, Patel J, Al Rifai M, **Dixon DL**, Shapiro MD. Expert Analysis: One Pill for Them All: Polypill Therapy for the Prevention of Cardiovascular Disease. American College of Cardiology. [Available here](#). Mar 19, 2021.
7. *De Jesus C, Teasley B, **Dixon DL**, Bucheit JD. Patient Case Quiz: ASCVD Risk Reduction in a Patient with Familial Hypercholesterolemia. American College of Cardiology. [Available here](#). August 4, 2020.
8. *Saeed A, **Dixon DL**, Yang E. Expert Analysis: Racial Disparities in Hypertension Prevalence and Management: A Crisis Control? [Available here](#). Apr 6, 2020.
9. *Patel J, Al Rifai M, **Dixon DL**, Shapiro MD. Patient Case Quiz: Primary Prevention of Atherosclerotic Cardiovascular Disease for Those at Intermediate Risk. [Available here](#). April 3, 2020.
10. Wiggins B, **Dixon D**. Smoking Cessation: It's a Team Sport. *Lipid Spin*. 2019;17(3):25-27.
11. *Anderson A, Caldas L, **Dixon DL**. LDL Limbo: How Low is Too Low? iForumRx. [Available here](#). October 26, 2018.
12. **Dixon DL**. The PREDIMED Study: Should the Mediterranean Diet be Recommended to Prevent Cardiovascular Disease? *Lipid Spin* 2017;15(4):20-21.
13. *Buckley L, **Dixon DL**. Are Statins "ALL-THAT" for Primary Prevention in Older Adults? A Second Look at ALLHAT LLT. iForumRx. [Available here](#). August 25, 2017.
14. Croy DS, **Dixon DL**, Kennedy L. Dyslipidemia & Antipsychotic Medications: Who is Monitoring the Lipids? *Lipid Spin* 2016; 14(2):7-9.
15. **Dixon DL**, Sisson EM. Lipid Illuminations: HPS2-THRIVE Commentary. *Lipid Spin* 2015; 13(1):16-17.
16. **Dixon DL**, Sisson EM. Ten Things Every Clinician Should Know About the 2013 ACC/AHA Lipid Guidelines. iForumRx. [Available here](#). November 26, 2013.
17. **Dixon DL**, Bolick JP, Godishala LM, Kris-Etherton PM, Nash DT, Neri L, Warren WS. Clinician's Toolkit: A Guide to Medication and Lifestyle Adherence. *Lipid Spin* 2013; 11(Suppl1):1-20.
18. *Siskey J, Lyles A, **Dixon DL**. Beta-Blockers and Hypertension, Where is the Data? iForumRx. Link not available. 2012.
19. *Coles T, **Dixon DL**. Another Bust for Omega-3 Fatty Acids – Is it Time to Go Fishing Elsewhere? iForumRx. [Available here](#). October 2012.
20. **Dixon DL**. Exenatide Before Prandial Insulin? – Not Just Yet! iForumRx. [Available here](#). February 2012.
21. **Dixon DL**. Venous Thromboembolism Prophylaxis in Patients with Multiple Myeloma. *U.S. Pharm.* 2013;38(3)(Oncology suppl):8-11.
22. **Dixon DL**. Hypertriglyceridemia Management in Patients with Diabetes. *U.S. Pharm.* 2009; 34(5)(Diabetes suppl):3-6.
23. **Dixon DL**, Kim J. Pharmacology Consult: The Current Status of Amiodarone Adverse Event Monitoring. *Cardiology Today*. 2014;16(12):32.

24. **Dixon DL.** Stroke and TIAs – Minimizing the Risk of Recurrence. *Pharmacy Times*. Dec 2009;64-66.

PUBLISHED PROFESSIONAL EDUCATION PROGRAMS

1. *Pharmacy-Based Hypertension Management*. American Pharmacists Association. Published [online](#) June 30, 2016.
2. *Hyperlipidemia Overview and the Clinical and Economic Burden*. Pharmacy Times CE. Published [online](#) March 31, 2025.
3. *Enhancing Access to Lipid-Lowering Therapies and Optimizing Cholesterol Management in Patients with Very High-Risk ASCVD*. Pharmacy Times CE. Published [online](#) April 2024.
4. *Understanding the Challenges of Homozygous Familial Hypercholesterolemia*. Pharmacy Times CE. Published [online](#) July 2023.
5. *The Impact of PCSK9 Modulation on Cardiovascular Outcomes: Recent Advances and the Managed Care Implications*. Pharmacy Times CE. Published [online](#) October 2022.
6. *NLA Scientific Statement on Statin Intolerance: A New Definition and Guidance on Managing Statin Intolerant Patients [Tweertorial]*. Cardiometabolic Medicine CME. Published [online](#) July 2022.
7. Croy D, **Dixon D**, Lundberg G. *Guideline Education: Lp(a) Is an Important Risk Marker to Prevent Coronary Artery Disease*. American College of Cardiology. Published [online](#) October 2019.
8. *2018 Update on Cholesterol Management and ASCVD Risk Reduction*. American Pharmacists Association. February 2019.
9. Co-Presented with Rhonda Cooper-DeHoff. *A Pharmacist's Guide to PCSK9 Inhibitors: From Patient Selection to Pharmacoeconomics*. Medscape Education. Published [online](#) December 2016.
10. *Cardiovascular Disease: Peripheral Arterial Disease*. Certified Geriatric Pharmacist (CGP) Review. American Society of Consultant Pharmacists. Published [online](#) October 2015.
11. *Cardiovascular Disease: Cardiac Arrhythmias*. Certified Geriatric Pharmacist (CGP) Review. American Society of Consultant Pharmacists. Published [online](#) October 2015.
12. *Cardiovascular Disease: Heart Failure*. Certified Geriatric Pharmacist (CGP) Review. American Society of Consultant Pharmacists. Published [online](#) October 2015.
13. *Arrhythmias in the Older Adult*. Certified Geriatric Pharmacist (CGP) Review. American Society of Consultant Pharmacists. Published [online](#) August 2015.
14. *Demystifying Metformin*. Foundation for Health Improvement & Technology: LecturePad.org. Published [online](#) January 10, 2015.
15. *Management of Hypertension Across the Lifespan*. Foundation for Health Improvement & Technology: LecturePad.org. Published [online](#). October 30, 2013.

SCHOLARLY COMMUNICATION, MEDIA, AND PUBLIC ENGAGEMENT

Creator and Host, [Voices in Pharmacy Innovation Podcast](#) (2026-Present)

- Founded and hosted a nationally oriented monthly podcast highlighting innovation in pharmacy practice and healthcare in collaboration with the VCU School of Pharmacy Center for Pharmacy Practice Innovation.
- Curate and lead in-depth interviews with national leaders, faculty scholars, clinicians, and professional organization leaders across academic and pharmacy practice settings.
- Translate emerging evidence, policy developments, and implementation strategies into accessible content for pharmacists, trainees, and health professionals.
- Contribute to the professional visibility of the VCU School of Pharmacy through sustained national dissemination and thought leadership.
- Episodes distributed via major podcast platforms (e.g., Apple Podcasts, Spotify).

Podcast Appearances

1. Virginia Hospital & Healthcare Association (VHHA) [Patients Come First podcast](#) (2026).
2. Guest Host, National Lipid Association Lipid Insights Podcast, “[Changing the FH Playbook: Diagnosis and Treatment Updates from the NLA](#)” (2026).
3. ACCP Journals Podcast (*JACCP*), “[Episode 152: PCSK9-directed Therapies](#),” with host Lindsay DeVane (2025).
4. iForumRx Podcast, “[Prescription for Savings, the Clinical and Economic Impact of Pharmacist-Led Hypertension Management in the US](#),” with host Stuart Haines (2024).
5. ReachMD *Heart Matters* Podcast, “[Pharmacist-Prescribing and Hypertension Management: An Economic Benefit](#),” with host Mary Katherine Cheeley (2023).
6. ACCP Journals Podcast, “[Episode 97: Clinical Practice Guidelines](#),” with host Jerry Bauman. February 13, 2023.
7. iForumRx Podcast, “[Beyond Statins: Approaches to Lipid Lowering in 2023](#),” with host Stuart Haines (2023).
8. Pharmacy To Dose: The Critical Care Podcast, “[HFpEF and Guideline/Consensus Document Writing](#),” with host Nick Peters (2023).
9. Pharmacy Quality Solutions Quality Corner Show Podcast, “[Aren’t All Pharmacists Clinical?](#)” with host Nick Dorich (2023).
10. Diverse Conversations Podcast, “[The Future of Pharmacy](#),” with host Aska Patel (2021).
11. CardioScripts Podcast, “[The EVAPORATE Trial](#),” with host Liz Sulaica (2020).
12. CardioScripts Podcast, “[Plenty of fish \[oil\] in the sea, have we REDUCEd-IT to one?](#)” with host Liz Sulaica (2020).
13. ACCP Journals Podcast (*JACCP*), “[Episode 18: A Social Media Primer for Pharmacists](#),” with host Ephrem Abebe (2019).
14. ACCP Journals Podcast (*Pharmacotherapy*), “Episode 21: Evolving Role of Non-Statin Therapy,” with host Stuart Haines (2018).
15. ReachMD *Lipid Luminations* Podcast, “[Triglyceride-Lowering Therapies: Addressing Gaps in the Guidelines](#),” with host Alan Brown (2016).

Media Quotes and Commentary

1. Pharmacy Times, “[First-Ever Guideline on Cardio-Kidney-Metabolic Syndrome Calls for Earlier Screening, Coordinated Care](#).” June 9, 2026.
2. Pharmacy Times, “[ADA 2026: Therapeutic Inertia, Access Barriers, and the Pharmacists’ Role in Closing the Cardiorenal Treatment Gap](#).” June 8, 2026.
3. Pharmacy Times, “[ADA 2026: The 2026 Standards – A Pharmacist’s Guide to Cardiorenal Risk Reduction](#).” June 5, 2026.
4. Pharmacy Today, “[BP control is a team effort](#).” November 2025;31(11):24-29.
5. Cardiovascular Business, “[FDA clears first generic versions of rivaroxaban—what it means for patient care](#).” March 18, 2025.
6. Medpage Today, “[Third-Generation PCSK9 Inhibitor Cuts Cholesterol With Single, Small, Monthly Shot](#).” April 9, 2024.

7. Medpage Today, "[Antisense Drug Slashes High Triglycerides – Two Trials Show Promise in Moderate and Extreme Elevations.](#)" April 8, 2024.
8. Medpage Today, "[Statins Reach More Patients with Pharmacist's Orders – Asynchronous automated order approach boosts statin prescribing.](#)" November 14, 2023.
9. tctMD, "[Similar Outcomes with Enteric-Coated and Uncoated Aspirin: ADAPTABLE.](#)" October 6, 2023.
10. Cardiology Advisor, "[Insight into the Updated AHA/ACC Guidelines on Treating Chronic Heart Disease.](#)" September 8, 2023.
11. tctMD, "[Migraine with Aura Doesn't Hone CV Risk Prediction in Middle-Aged Women.](#)" June 8, 2023.
12. tctMD, "[Oral PCSK9 Inhibitor Reduces LDL Cholesterol in Phase IIb Study.](#)" March 11, 2023.
13. Pharmacy Learning Network (Talking Therapeutics), "[High-Density Lipoprotein: Too Much of a Good Thing?](#)" January 26, 2022.
14. Virginia Mercury, "[Virginia pharmacists report growing demand for experimental COVID-19 medications.](#)" March 27, 2020.
15. Cardiology Today, "[Perspective on: Meta-analysis provides new insights on CV risk with rosiglitazone.](#)" February 13, 2020.
16. Pharmacy Today, "Confused about statin benefits? New AHA statement has answers." March 2019;25(3):19.
17. Men's Health, "[7 Drugs You're Taking That Might be Wrecking Your Workout.](#)" August 29, 2017.
18. Pharmacy Today, "PCSK9 inhibitor prescriptions require extra resources." August 2017;23(8):40.
19. Richmond Times-Dispatch, "[Your Health: Pharmacies that dispense heart rhythm drug require special certification.](#)" June 22, 2014.
20. MedPage Today, "LDL No Longer Target of Kidney Disease Lipid Management." December 9, 2013.
21. Bloomberg News, "Annual Doctor Visits Will Increase Cholesterol Drug Use." November 14, 2013.

News and Media Features

1. Feature, MedPage Today, "[Pharmacist Prescribing for BP Control Makes Economic Sense.](#)" November 3, 2023.
2. Video Interview, Pharmacy Times, "[Heart Failure Treatments in the Pipeline Focus on Stimulating Heart Muscle.](#)" April 13, 2022.
3. Feature, Pharmacy Times, "[Community Pharmacies Implement Innovative 24-hour Ambulatory Blood Pressure Monitoring Service.](#)" December 9, 2020.
4. Feature, SunTech Medical, "[Ambulatory Blood Pressure Monitoring in the Community Pharmacy.](#)" February 7, 2020.

Radio Interviews

1. Richmond's Morning News on 1140 WRVA 1140, "No more preventive aspirin?" March 19, 2019.
2. Jimmy Barrett Show on 1140 WRVA. "Statins for More People." July 16, 2015.

TEACHING AND MENTORING

VCU School of Pharmacy

Course Coordination (*courses developed or revised)

- *The US Health Care System (1.5 credits, P1) 2026
- Contemporary Pharmacy Practice (3 credits, P1) 2024
- *Pathophysiology and Patient Assessment Skills (3 credits, P1) 2014, 2024-Present
- *Advanced Cardiology Elective Course (2 credits, P2/P3) 2013-2021
- Clinical Therapeutics Module: Cardiovascular (4.5 credits, P1) 2012-2020, 2026-Present
- Independent Research Elective Course (1-2 credits, P2/P3) 2012-Present

Didactic Teaching (selected lectures)

- Clinical Therapeutics Modules
 - Gout (2 hours, P3) 2024
 - Dyslipidemia (6 hours, P1) 2023-Present
 - Complex Cardiology Cases (2 hours, P3) 2013-2021
 - Cardiac Arrhythmias (4 hours, P2) 2013-2020
- Evidence-Based Pharmacy
 - Clinical Practice Guidelines (2 hours, P3) 2023-Present
 - Information Mastery (2 hours, P3) 2016-2017
- Academic Pharmacy Elective
 - Faculty Hiring, Evaluation, and Promotion (2 hours, P2/P3) 2018-Present
- Pathophysiology and Patient Assessment Skills
 - Basic Patient Assessment (2 hours, P1) 2025-Present
 - Cardiovascular Disease (2 hours, P1) 2015-2018, 2024-Present
- Advanced Cardiology Elective
 - Dyslipidemia (4 hours, P2/P3) 2013-Present

Small Group/Lab Facilitator

- Pathophysiology and Patient Assessment Skills (~4-6 hours annually) 2014-Present
- Evidence-Based Pharmacy (~2 hours annually) 2014-Present
- Foundations Course Sequence (~4-8 hours annually) 2012-Present

Pharm.D. Experiential Teaching (Preceptor)

- Tele-rotation during COVID-19 (121 students) Apr/May 2020
- Advanced Pharmacy Practice Experience, Ambulatory Care (~12 students annually) 2012-2018
- Introductory Pharmacy Practice Experience, Service Learning (~4 students annually) 2012-Present

Pharmacy Resident Experiential Teaching (Preceptor)

- Ambulatory Care Longitudinal Rotation (~2 residents annually)
 - VCU School of Pharmacy Residency Programs 2013-2026
 - VCU Health Pharmacy Residency Programs 2012-Present

Formal Student Mentoring

- Continuous Professional Development Course (P1-P3) (~10 students annually) 2018-Present
- Mentoring and Advising Program for Students (P1-P3) (~10 students annually) 2014-2017

Mentored Student/Trainee Awards

- Trevor Sproule (P2), VCU School of Pharmacy Summer Fellowship (\$4,000) 2023
- Christine Tran (P3), ACPP Futures Grant Student Award (\$5,000) 2022-2023
- Christine Tran (P2), VCU School of Pharmacy Summer Fellowship (\$4,000) 2021
- Sarah Khaddage (P2), VCU School of Pharmacy Summer Fellowship (\$4,000) 2020
- Aleandra Cox (P2), VCU School of Pharmacy Summer Fellowship (\$4,000) 2019

Mentored Faculty Training Award

- Teresa Salgado, PhD (Assistant Professor) 2020-2022
K12 Mentored Training in Implementation Science, Washington University School of Medicine

Graduate Student Advisory Committees

- Olajumoke Babatunde, PhD Candidate, Primary advisor: Elvin Price, PharmD, PhD 2022-2026
- Poorva Birari, MS Candidate, Primary advisor: Teresa Salgado, PhD 2022-2024
- Khalifa Alrajeh, PhD Candidate, Primary advisor: Youssef Roman, PharmD, PhD 2022-2024
- Natalie Bohmke, PhD Candidate, Primary advisor: Danielle Kirman, PhD 2022-2025
- Jessica Jay, MS Candidate, Primary advisor: Julie Patterson, Pharm.D., PhD 2021-2022
- Tyler Wagner, PhD Candidate, Primary advisor: Teresa Salgado, PhD 2019-2023
- Rotana Radwan, PhD Candidate, Primary advisor: Teresa Salgado, PhD 2019-2023

Post-Doctoral Fellow Advising, Cardiovascular Pharmacotherapy

- Ibrahim Alhomoud, PharmD, Primary advisor: Dave Dixon, PharmD 2022-2023
- Azita Talasaz, PharmD, Primary advisor: Ben Van Tassell, PharmD 2020-2023
- Ai-Chen Ho, PharmD, Primary advisor: Ben Van Tassell, PharmD 2019-2021
- George Wohlford, PharmD, Primary advisor: Ben Van Tassell, PharmD 2017-2020
- Leo Buckley, PharmD, Primary advisor: Ben Van Tassell, PharmD 2015-2017

VCU School of Nursing

Didactic Teaching (selected lectures)

- Advanced Nursing Practice Pharmacotherapeutics Course
 - Atrial Fibrillation, Anticoagulation, Heart Failure (6 hours) 2013-2016

PROFESSIONAL SERVICE

Invitation-Only Expert Roundtables hosted by the American College of Cardiology

- Advancing Gene Editing Therapy for Cardiovascular Disease June 4, 2025
- Risk to Resilience: Addressing Weight Management in Cardiovascular Care May 22, 2024
- From Pressure to Problems: Navigating the Impact of Hypertension on Cardiovascular Disease May 13, 2024
- Managing Cardiovascular Risk in Diabetes Dec 3, 2018
- Cardiovascular Disease Risk Communication for Patients and Their Clinicians Oct 17, 2018
- Effective Prior Authorization: Right Drug, Right Patient for Cardiovascular Treatment Oct 12, 2017
- Managing Cardiovascular Risk in Diabetes June 20, 2017
- Cardiometabolic Think Tank June 20, 2014

Other Consultant and Stakeholder Work

- American College of Cardiology Stakeholder Representative 2021-2024
 - BESTMED: Observational Evaluation of Second-Line Therapy Medications in Diabetes study; funded by PCORI; PI: Alexander Turchin, MD, MS (Harvard University)

Editorial Roles

- Deputy Editor, *Journal of Clinical Lipidology* 2026-Present
- Editorial Board, *Pharmacotherapy* 2026-Present
- Associate Editor, *Journal of Clinical Lipidology* 2021-2026
- Section Editor, Emerging Concepts in Therapeutics, *Journal of Cardiovascular Pharmacology* 2020-2022
- Editorial Board, *Diabetes/Metabolism: Research and Reviews* 2020-2023
- Associate Editor, *Journal of the American Pharmacists Association* 2019-2025
- Editorial Board, ACC.org Pulse Check 2019-2021

- Associate Editor, *PLoS One* 2018-2019
- Series Editor, Ambulatory Care Self-Assessment Panel (ACSAP) 2017-2021
- ACC.org Cardiovascular Team 2015-2017
- Social Media Editor, iForumRx.org 2014-2016
- Editorial Board, *Journal of Clinical Lipidology* 2008-Present

Ad Hoc Peer Review (Selected Journals)

- *Lancet*, *Circulation*, *Circulation: Cardiovascular Quality and Outcomes*, *European Heart Journal*, *European Heart Journal-Cardiovascular Pharmacotherapy*, *Journal of the American College of Cardiology*, *Clinical Cardiology*, *Pharmacotherapy*, *Journal of Clinical Hypertension*, *Journal of the American College of Clinical Pharmacy*, *American Journal of Health-System Pharmacists*

Clinical Practice Guideline Peer Review (Invited)

- 2026 AHA/ACC Dyslipidemia Guideline, Peer Review Committee Member
- 2023 & 2024 ADA Standards of Care in Diabetes, Section 10. Cardiovascular Disease and Risk Management
- 2021 ACC/AHA Guideline for the Evaluation and Diagnosis of Chest Pain
- 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients with Hypertrophic Cardiomyopathy
- 2020 ACC/AHA Guideline for the Management of Patients with Valvular Heart Disease
- 2018 ACC/AHA Guideline on the Management of Blood Cholesterol
- 2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults

Abstract Review

- American Heart Association Hypertension Scientific Sessions 2020-2024
- National Lipid Association Scientific Sessions 2019-2021
- American College of Cardiology Scientific Sessions 2017-2025
- American College of Clinical Pharmacy Annual Meeting 2016-Present

Grant Review

- ACC National Cardiovascular Data Registries: PINNACLE and Diabetes Collaborative 2019-2022
- AACP New Investigator Award 2019
- ACCP Cardiology PRN Seed Grant 2017-2019
- ACCP Ambulatory Care PRN Seed Grant 2012-2017

Conference Organizing Activities

- Invitational Summit on State Medicaid Pharmacist Payment Programs. Hosted by the VCU School of Pharmacy Center for Pharmacy Practice Innovation. Virtual; March 7, 2025.
- Diabetes Health Humanities Symposium. Sponsored by 4-VA. Virtual; November 20, 2020.
- Pre-Conference Workshop: Best Practices for Implementing Team-Based Primary Care. 7th Annual Jewell and Carl F. Emswiler Interprofessional Symposium; Richmond, VA; February 1, 2019.
- Pharmacist Training in Collaborative Care: Retooling for the Future. VCU Alumni House; Richmond, VA; June 9-10, 2017.

Professional Organization Committee, Leadership, and Service Activities

American College of Clinical Pharmacy

• <i>Chair</i> , Publications Committee	2024-2025
• Member, Nominations Committee (Cardiology PRN)	2024-2025
• Member, Best Poster (Student) Judge Panel	2023
• <i>Chair</i> , Task Force on Treatment Guidelines	2021-2022
• <i>Chair</i> , Programming Committee (Cardiology PRN)	2020-2021
• <i>Chair</i> , Cardiology PRN	2020-2021
• <i>Chair-elect</i> , Cardiology PRN	2019-2020
• Member, Certification Affairs Committee	2019-2020
• Member, Budget and Finance Committee (Ambulatory Care PRN)	2019-2020
• <i>Co-Chair</i> , Research and Scholarship Committee (Cardiology PRN)	2018-2019
• Member, Best Poster Judge Panel	2018
• Member, Scholarly Activities Committee (Ambulatory Care PRN)	2017-2018, 2024-2025
• Member, Research and Scholarship Committee (Cardiology PRN)	2017-2018
• Member, Education Committee (Ambulatory Care PRN)	2016-2017
• <i>Chair</i> , Communications Committee (Cardiology PRN)	2015-2016
• Member, Research Process Committee (Ambulatory Care PRN)	2015-2016
• Member, Research Committee (Ambulatory Care PRN)	2013-2015
• Member, Publications Committee	2012-2013
• Member, Membership Committee	2009-2010
• Nominations Committee (Ambulatory Care PRN)	2008-2009, 2016-2017
• Member, Communications Committee (Ambulatory PRN)	2007-2008

American College of Cardiology (ACC)

• ACC Representative, ADA Standards of Care in Diabetes Guidelines	2025-2026
• Member, ACC/AHA Joint Committee on Clinical Practice Guidelines	2019-2020, 2025-2027
• Member, Awards Committee	2024-2027
• Member, Chronic Coronary Disease Guideline Dissemination Work Group	2023
• Member, Clinical Policy Approval Committee	2022-2025
• <i>Co-Chair</i> , Dyslipidemia Work Group, Prevention Council	2018-2024
• Member, Scientific Sessions Programming Committee, Prevention Section	2021-2024
• Member, Prevention of Cardiovascular Disease Section Leadership Council	2021-2024
• <i>Elected</i> , Cardiovascular Team Chapter Representative (Virginia ACC Chapter)	2021-2024
• Member, PINNACLE/Diabetes Registry Research & Publications Subcommittee	2019-2022
• Member, Member Well Being Work Group	2019-2020
• Member, Membership Committee	2018-2021
• Member, Credentialing and Member Services Committee	2015-2021
• Member, Cardiac Care Team Committee (Virginia ACC Chapter)	2012-2024

National Lipid Association

• Member, Advocacy Committee	2020-2024
• <i>Co-Chair</i> , Scientific Publications Committee	2020-2025
• <i>President</i> , Southeast Lipid Association (SELA) Regional Chapter Board	2020-2021
• <i>President-elect</i> , Southeast Lipid Association (SELA) Regional Chapter Board	2019-2020
• Member, 2018 Cholesterol Guideline Dissemination Task Force	2018-2019

- *Treasurer*, Southeast Lipid Association (SELA) Regional Chapter Board 2018-2019
- Member, Finance Committee 2017-2018
- Member, Dues Task Force 2017-2018
- *Co-Chair*, Social Media Committee 2017-2020
- *Co-Chair*, Interprofessional Continuing Education Committee 2017-2019
- *Secretary*, Southeast Lipid Association (SELA) Regional Chapter Board 2017-2018
- Member, Scientific Sessions Meeting Planning Committee 2016-2017
- Member, Publications Committee 2015-2016
- *At-Large Board Member*, Southeast Lipid Association (SELA) Regional Chapter Board 2014-2016
- Member, Patient Adherence Subcommittee 2012-2013

Accreditation Council for Clinical Lipidology (became American Board of Clinical Lipidology in 2022)

- *President*, Board of Governors Executive Committee 2021-2022
- *Vice-President*, Board of Governors Executive Committee 2019-2021
- *Treasurer*, Board of Governors Executive Committee 2018-2019
- *At-Large Board Member*, Board of Governors Executive Committee 2015-2018

American Heart Association (AHA)

- Member, Science Advisory Panel, Cardiovascular Kidney Metabolic Health Initiative 2025-2027
- Member, Clinical Pharmacology Committee (Council on Clinical Cardiology) 2025-2028
- Member, Workgroup on Assessing the Benefits of GLP-1 RAs for CV Risk Reduction 2022-2023
- Member, Clinical Programming Subcommittee (Council on Hypertension) 2020-2024
- *Co-Captain*, Richmond Heart Walk 2015-2016

American Pharmacists Association (APhA)

- Member, Advisory Board, for the Pharmacy-Based Hypertension Advanced Training Program 2025-2026

INSTITUTIONAL SERVICE

Virginia Commonwealth University

- *Elected member*, Faculty Senate 2017-2020
 - Member, Faculty Affairs Committee 2019-2020
 - Member, Academic and Professional Status Committee 2017-2019
- Member, Real World Experience Steering Subcommittee 2017
- *Elected member*, University Council 2014-2016

VCU School of Pharmacy

- Member, Director of Communications Search Committee 2023
- Member, Expedited Tenure Review Committee for K.C. Ogbonna, PharmD 2023
- Member, Dean Search Committee 2022
- Member, Executive Committee 2021-Present
- Member, Academic Integrity Task Force 2021-2022
- *Chair*, Outcomes and Assessment Committee 2020-2021
- Member, Next Generation Pharmacist Curriculum Task Force 2019-2022

- Member, Academic Performance Committee 2018-2019
- Member, Curriculum Committee 2018-2020
- Member, Diversity Committee 2018-2019
- Member, Associate Dean for the Office of Experiential Education Search Committee 2017
- Member, Strategic PharmD Recruitment Task Force 2016
- *Chair*, PharmD Admissions Committee 2015-2017
 - Member 2013-2017
- *Elected member*, Promotion and Tenure Guidelines Committee 2013-2015

Department of Pharmacotherapy & Outcomes Science

- Founding member, Collegiality Committee 2023-Present
- *Chair*, P&T Review Committee for John Bucheit, PharmD 2020
- *Chair*, Search Committees for Oncology and Ambulatory Care faculty 2019
- Member, Entrustable Professional Activities Work Group 2017-2019
- Member, Health Services and Outcomes Science Faculty Search Committee 2016, 2017-2018
- *Chair*, Ambulatory Care, Pediatrics, and Psychiatry Faculty Search Committee 2017
- Member, Ambulatory Care Faculty Search Committee 2015
- Member, Service-Learning Subcommittee 2014-2015
- Member, Student Mentoring and Advising Committee 2013-2015

VCU Health

- Member, Preventive Cardiologist Search Committee 2023
- *Co-Lead*, Diabetes Care Model Redesign 2018-2020
- Member, Vision by Design: Clinical Delivery Model Work Group 2018
- Member, Collaborative Practice Work Group 2016

ACTIVE PROFESSIONAL MEMBERSHIPS

American Pharmacists Association (APhA)	2017-Present
Virginia Pharmacists Association (VPhA)	2016-Present
American Heart Association (AHA)	2015-Present
American Association of Colleges of Pharmacy (AACP)	2012-Present
American College of Cardiology (ACC)	2012-Present
National Lipid Association (NLA)	2006-Present
American College of Clinical Pharmacy (ACCP)	2005-Present
Campbell University Pharmacy Alumni Association	2005-Present

COMMUNITY SERVICE ACTIVITIES

Volunteer teaching assistant (part-time), Grandmaster Dong's Martial Arts	2025-Present
Participant, Annual Karate-Thon Fundraiser, Children's Hospital of Richmond	2021-Present
Food distribution volunteer, Chesterfield Food Bank	2025-Present